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Monoamine oxidase A (MAO-A) is a mitochondrial flavoenzyme implicated in the pathogenesis of atherosclerosis and
inflammation and also in many neurological disorders. MAO-A
also has been reported as a potential therapeutic target in prostate cancer. However, the regulatory mechanisms controlling
cytokine-induced MAO-A expression in immune or cancer cells
remain to be identified. Here, we show that MAO-A expression
is co-induced with 15-lipoxygenase (15-LO) in interleukin 13
(IL-13)-activated primary human monocytes and A549 nonsmall cell lung carcinoma cells. We present evidence that
MAO-A gene expression and activity are regulated by signal
transducer and activator of transcription 1, 3, and 6 (STAT1,
STAT3, and STAT6), early growth response 1 (EGR1),
and cAMP-responsive element– binding protein (CREB), the
same transcription factors that control IL-13– dependent
15-LO expression. We further established that in both primary monocytes and in A549 cells, IL-13–stimulated MAO-A
expression, activity, and function are directly governed by
15-LO. In contrast, IL-13– driven expression and activity of
MAO-A was 15-LO–independent in U937 promonocytic
cells. Furthermore, we demonstrate that the 15-LO– dependent transcriptional regulation of MAO-A in response to
IL-13 stimulation in monocytes and in A549 cells is mediated
by peroxisome proliferator–activated receptor ␥ (PPAR␥)
and that signal transducer and activator of transcription 6
(STAT6) plays a crucial role in facilitating the transcriptional
activity of PPAR␥. We further report that the IL-13–STAT6 –
15-LO–PPAR␥ axis is critical for MAO-A expression, activity, and function, including migration and reactive oxygen
species generation. Altogether, these results have major
implications for the resolution of inflammation and indicate
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that MAO-A may promote metastatic potential in lung cancer cells.

Interleukin (IL)4 13 is a Th2 cytokine that is involved in regulating inflammatory responses and is thought to play a major
role during asthma and allergic reactions (1). However, IL-13
primarily acts as an anti-inflammatory molecule that activates
monocytes/macrophages toward the M2a phenotype leading to
the up-regulation of several genes involved in the resolution of
inflammation (2–5). Among the most strongly up-regulated
genes in IL-13–activated monocytes/macrophages with potential anti-inflammatory properties are 15-lipoxygenase (15-LO)
and monoamine oxidase A (MAO-A) (1, 6 –10).
During alternative activation of monocytes/macrophages,
IL-13 interacts with a specific cell-surface receptor that utilizes
the IL-4R␣ chain, which combines with and signals through
IL-13R␣1 (type II IL-4R, receptor for IL-13) (11). The receptorassociated Jaks that are attached to the type II IL-4R and are
stimulated by IL-13 treatment include Jak2 and Tyk2 (1). Jakmediated activation of Stat proteins leads to Stat translocation
and DNA binding thus activating transcription of target genes.
In addition to Stat tyrosine phosphorylation, Stat transcriptional activity is also enhanced by serine phosphorylation. The
involvement of several Ser/Thr kinases, including p38 MAPK,
ERK1/2, and PKC␦, in regulating Stat serine phosphorylation
and Stat-dependent gene transcription, has already been demonstrated (12–15). Stat proteins dimerize after tyrosine phos4

The abbreviations used are: IL, interleukin; 15-LO, 15-lipoxygenase; MAO-A,
monoamine oxidase A; ODN, oligodeoxyribonucleotide; ROS, reactive oxygen species; PPAR␥, peroxisome proliferator-activated receptor-␥; Jak,
Janus kinase; Stat, signal transducer and activator of transcription; CREB,
cAMP-responsive element– binding protein; BCS, bovine calf serum; MT,
mutated; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; DMEM, Dulbecco’s modified Eagle’s medium; EMT, epithelial to
mesenchymal transition; HODE, hydroxyoctadecadienoic acid; HPODE,
hydroperoxylinoleic acid; HPETE, hydroperoxyeicosatetraenoic acid;
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phorylation by the Src homology 2–phosphotyrosine interaction, which enables the proteins to be efficiently transported to
the nucleus and to bind DNA. DNA binding facilitates the
interaction of Stat transcription factors with other proteins and
enhances the transcriptional efficiency of the Stat-dependent
genes. Jak-mediated activation of Stat1, Stat3, and Stat6 seems
to be critical during activation of monocytes/macrophages
by IL-13 stimulation and significantly contributes to the IL13–activated gene expression. IL-13 signaling utilizes both
IL-4R␣–Jak2–Stat3 and IL-13R␣1–Tyk2–Stat1/Stat6 pathways to regulate the expression of some critical inflammatory
genes, including 15-LO and MAO-A (1).
15-LO is a lipid-peroxidating enzyme that is substantially
induced in human peripheral blood monocytes after IL-4/IL-13
activation. This enzyme is capable of oxygenating polyunsaturated fatty acids like linoleic and arachidonic acids to their
corresponding hydroperoxides like (13S)-HPODE and (15S)HPETE (16, 17), which have been implicated as inflammatory
mediators in cell development and in the pathogenesis of various diseases (18 –21). In contrast, MAO-A is a catalytically
active flavoprotein that catalyzes the oxidative deamination of
biogenic and dietary amines like serotonin, dopamine, norepinephrine, and tyramine and converts them into their corresponding aldehydes and reactive oxygen species (ROS) (22–25).
This pro-oxidative enzyme is encoded by the X chromosome
and is located in the outer mitochondrial membrane and cytosol (26). MAO-A hyperactivity has been shown to be associated
with depression, and previous reports implicate MAO-A inhibitors as effective therapeutics against clinical depression and
anxiety (27, 28). Previous studies further demonstrated the
involvement of MAO-A in neurodegenerative diseases, including Parkinson’s and Alzheimer’s disease, by inducing oxidative
stress–mediated apoptosis (29, 30). MAO-A deficiency and
abnormal activity has been associated with impulsive aggressive behavior (31), neuropsychiatric disorders (32), pancreatic
beta-cell function (33), and glucose metabolism (34). MAO-A
has also been reported as a vital regulator of embryonic brain
development (25). In addition to neuroinflammatory syndromes, involvement of MAO-A has been established in the
pathogenesis of many cardiovascular disorders. The predominant role of MAO-A has been shown in myocardial injury (35),
heart failure (36), cardiac cell apoptosis (37), and vascular wall
remodeling (38). Although MAO-A is associated with resolution of inflammation, MAO-A–mediated ROS generation and
subsequent oxidative stress could promote inflammation in
cardiovascular diseases. The role of MAO-A in promoting or
resolving inflammation may rely on the delicate balance of ROS
formation and catabolism. Depending on the cellular expression level of MAO-A, this balance is maintained and can influence many pathogenic pathways that are involved in all of
these disease conditions. Recent evidence also suggests that
increased MAO-A expression is associated with prostate tumor
growth and metastasis (39).
Although activation of MAO-A has been reported by IL-13
in monocyte/macrophage system, several monocytic cell lines
fail to induce MAO-A expression in response to IL-13 stimulation. In contrast, U937 cells (pro-monocytic, human myeloid
leukemia cell line), which exhibit many characteristics of

monocytes and are used as the experimental model to elucidate
mechanisms of monocyte and macrophage differentiation, can
induce MAO-A expression after IL-13 stimulation. Induction
of MAO-A has also been observed in an IL-13–induced nonmonocytic cell line, A549 (human lung epithelium carcinoma
cell line). The regulatory mechanisms controlling MAO-A gene
expression after IL-13 activation have yet to be explored in
monocytes/macrophages, pro-monocytic cells like U937 cells,
and in A549 lung cancer cells.
In this study, we demonstrated that MAO-A is co-induced
with 15-LO in monocytes/macrophages, normal human bronchial epithelial (NHBE) cells, and in the A549 lung epithelial
carcinoma cell line in response to IL-13 treatment, but it is
neither present nor induced by IL-13 in monocytic cell lines like
THP1 or Monomac6. In contrast, only MAO-A but not 15-LO
gene is induced by IL-13 in the promyelomonocytic cells like
U937. We investigated the mechanisms involved in regulating
the expression/activity and function of MAO-A during IL-13–
activation, and we presented evidence that Stat6, 15-LO,
and PPAR␥ are the critical regulators that are involved in controlling MAO-A gene expression and activity in monocytes/
macrophages and A549 cells, which further demonstrated the
concerted mechanistic effects of these genes during IL-13–
activation. However, IL-13–activated MAO-A gene expression/
activity in U937 cells is independent of 15-LO showing completely different gene regulation in U937 cells. We further
showed that PPAR␥ and 15-LO both are directly involved in
regulating the function of MAO-A–mediated migration
and ROS generation in monocytes/macrophages and in
A549 cells after IL-13 activation. Altogether, the IL-13 ⬎
STAT6 ⬎ 15-LO ⬎ PPAR␥ signaling pathways for regulating
MAO-A gene expression and function add novel insights
into the resolution of inflammation and in the progression of
lung cancer.

Results
MAO-A co-induces with 15-LO during IL-13 activation of
primary monocytes and A549 cells but not in IL-13–activated
U937 monocytic cells
In human peripheral blood monocytes, IL-13 up-regulates
expression of a variety of gene products (1), and one of the most
strongly up-regulated proteins is the lipid-peroxidizing enzyme
15-LO (6). To study the impact of this Th2-cytokine on monocyte cell physiology more comprehensively, the gene expression pattern was checked after culturing the cells in the
presence and absence of IL-13. We performed the IL-13 doseresponse and IL-13–mediated time-course experiments in primary monocytes and in A549 cells to determine the relative
responsiveness in these cells. Previous results from our group
and other groups already reported the IL-13– dependent dose
response and time course for the measurement of 15-LO at
protein and mRNA levels in primary monocytes (7, 12, 40).
These results demonstrated the optimal condition for 15-LO
mRNA and protein expression levels after 24- and 48-h incubations with 2 nM IL-13. We found similar conditions (48-h stimulation with 2 nM IL-13) for the maximal expression of MAO-A
protein both in primary monocytes and in A549 cells (Fig. S1,
J. Biol. Chem. (2018) 293(36) 14040 –14064
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Figure 1. MAO-A is co-induced with 15-LO in primary human monocytes and in A549 cells by IL-13 but not in U937 monocytic cells. Primary blood
monocytes, Monomac6, THP1, A549, and U937 cells (5 ⫻ 106/group) were treated with IL-13 (2 nM) for 24 h (mRNA) or 48 h (protein). A, C, E, G, and J, total cellular
RNA extracts were prepared and subjected to real-time PCR analysis. After normalization with GAPDH amplification, the fold induction of 15-LO mRNA (A and
E) and MAO-A mRNA (C, G, and J) expression for different groups was plotted. Data are the mean ⫾ S.D. (n ⫽ 3). For protein expression, cell lysates (50 g of
postnuclear extracts/lane) were resolved by 10% SDS-PAGE and immunoblotted with antibody against 15-LO (upper panels of B, F, and I) and MAO-A (upper
panels of D, H, and K). To confirm equal loading, the blots were then stripped and reprobed either with ␤-tubulin (lower panels of B, D, and I) or with PKC␦ (lower
panels of F, H, and K) antibodies. Arrows indicate the predicted migration of 15-LO, MAO-A, ␤-tubulin, and PKC␦ as determined by the migration of molecular
mass markers in the adjacent lanes. Data are from a representative of three repeat experiments showing similar results.

A–D) and for 15-LO protein in A549 cells (Fig. S1E). Following
these standardized conditions, we show that 15-LO gene
expression is substantially up-regulated in alternatively activated monocytes by IL-13 both at mRNA (more than 4000-fold
induction after incubation with IL-13 for 24 h, see Fig. 1A) and
at protein levels (after 48 h of IL-13 incubation, see Fig. 1B),
whereas IL-13–activated monocytic cell lines such as monomac
and THP1 do not show any induction of 15-LO (Fig. 1B). To test
whether 15-LO expression is paralleled by augmented MAO-A
expression in peripheral blood monocytes, our group further
shows that treatment of human peripheral blood monocytes

14042 J. Biol. Chem. (2018) 293(36) 14040 –14064

with IL-13 strongly induces the expression of MAO-A both at
the mRNA (around 90-fold induction in response to IL-13
stimulation after 24 h, see Fig. 1C) as well as at the protein level
(Fig. 1D). Similar to 15-LO, IL-13 stimulation does not show
any induction of MAO-A in monomac and THP1 cells (Fig.
1D). A recent report demonstrated the ability of MAO-A to
induce epithelial to mesenchymal transition and thus enhance
growth, invasiveness, and metastasis of prostate cancer cells
(39), and we tried to investigate whether IL-13 induces MAO-A
expression in different other epithelial cancer cells. Our results
show that although MAO-A is constitutively present in many of
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these cells like HCT116 colorectal cancer cells or PC3 prostate
cancer cells (data not shown), co-induction of both 15-LO and
MAO-A occurs only in A549 lung epithelial carcinoma cells
after IL-13 stimulation both at the mRNA (Fig. 1, E and G,
respectively) as well as at the protein level (Fig. 1, F and H,
respectively). Because of the inducible nature of MAO-A gene
expression in A549 cells (same as monocyte/macrophage system), we continued our studies by testing this specific cell line
and tried to uncover the mechanistic details of MAO-A expression after IL-13 stimulation in both monocytes/macrophages as
well as in A549 cells.
U937 is a pro-monocytic, human myeloid leukemia cell line
that has many common characteristics of monocytes and is
extensively used as a model monocytic system to investigate
the mechanisms involved in either monocyte– endothelium
attachment or the differentiation of pro-monocytes into
mature monocytes or into macrophages. Hence, we wanted to
identify whether the same regulatory mechanisms for IL-13–
driven MAO-A gene expression/activity exist in immature
(U937 cells) and in mature monocytes. Our experimental
results with U937 cells (promyelomonocytic cell line) show a
significant increase of MAO-A mRNA (around 30-fold induction after IL-13 activation for 24 h, see Fig. 1J) and protein levels
(after 48 h of incubation with IL-13, see Fig. 1K). Surprisingly, IL-13 failed to induce 15-LO expression in U937 cells
after 48 h of IL-13 stimulation (Fig. 1I). These results indicate that IL-13–mediated MAO-A induction parallels 15-LO
up-regulation in peripheral blood monocytes and in A549
cells but not in U937 cells, which indicates that regulation of
MAO-A gene expression by IL-13 may be correlated with the
up-regulation of 15-LO expression in primary monocytes
and in A549 cells but may proceed via a 15-LO–independent
pathway in U937 cells.
Induction of 15-LO and MAO-A gene expression occurs in
alternatively activated monocytes by IL-13 but not in
conventionally activated monocytes by LPS or IFN␥
To examine whether 15-LO and MAO-A genes are specifically up-regulated in alternatively activated monocyte/macrophages by IL-13, we conducted several new experiments where
we compared our data (in alternatively activated monocyte/
macrophages by IL-13) with conventionally activated monocyte/macrophages in response to LPS or IFN␥. Our results,
included in Fig. S2, A–D, demonstrate that 15-LO and MAO-A
genes are up-regulated in alternatively activated monocyte/
macrophages by IL-13 at mRNA (Fig. S2, A and B) and at protein levels (Fig. S2, C and D), although these genes are not
expressed or induced in conventionally activated monocyte/
macrophages by LPS (Fig. S2, A–D). Further comparative
experiments with IFN␥ also show that when 15-LO and
MAO-A genes (at mRNA level) are induced by IL-13 activation,
there is practically very little/no induction of either 15-LO or
MAO-A genes after IFN␥ stimulation alone or in combination
with IL-13 (Fig. S2, E and F). These results thus confirm the
significance of the impact of IL-13 on 15-LO or MAO-A in
alternatively activated monocyte/macrophages.

Figure 2. MAO-A is overexpressed in H1299 lung cancer cells and not
induced by IL-13, whereas it is co-induced with 15-LO in normal human
bronchial epithelial cells after IL-13 stimulation. H1299 non-small cell
lung cancer cells and NHBE cells were incubated with IL-13 (2 nM i.e. 30 ng/ml)
for 48 h (for H1299 protein), 72 h (for NHBE mRNA), or for the indicated time
intervals (for NHBE protein). A, B, D, and F, cell lysates (50 g of postnuclear
extracts/lane) were resolved by 10% SDS-PAGE and immunoblotted with
antibody against 15-LO (upper panels of A and D) and MAO-A (upper panels of
B and F). In the upper panel of A, recombinant 15-LO (0.1 g) was used as a
standard. To confirm equal loading, the blots were then stripped and reprobed with ␤-tubulin antibody. Arrows indicate the predicted migration of
15-LO, MAO-A, and ␤-tubulin as determined by the migration of molecular
mass markers in the adjacent lanes. C and E, total cellular RNA extracts were
prepared and subjected to real-time PCR analysis. After normalization with
GAPDH amplification, the fold induction of 15-LO mRNA (C) and MAO-A
mRNA (E) expression for different groups was plotted. Data are the mean ⫾
S.D. (n ⫽ 3). Data are from a representative of two repeat experiments showing similar results.

MAO-A is constitutively expressed in H1299 NSCLC cells,
whereas IL-13 stimulation leads to concordant 15-LO and
MAO-A expression in NHBE cells
We further investigated whether in many other epithelial
cancer cells like in H1299 NSCLC or in HCT116 colorectal
cancer cells, concordant 15-LO and MAO-A induction is present or not following IL-13 stimulation. In H1299 cells, 15-LO
expression level is very low and is not induced by IL-13 (Fig.
2A). In contrast, MAO-A is constitutively overexpressed in
H1299 cells but is not further induced upon IL-13 stimulation
(Fig. 2B). A similar type of constitutive MAO-A overexpression
is found in HCT116 cells, and here also the MAO-A level is not
induced upon IL-13 activation (data not shown). So these
results thus demonstrate that in H1299 NSCLC and in other
J. Biol. Chem. (2018) 293(36) 14040 –14064
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Figure 3. In IL-13–stimulated monocytes, Stats (Stat1, Stat3, and Stat6) bind to their cognate DNA-binding sequences located in the 15-LO promoter.
A, predicted transcription factor-binding sites of 15-LO upstream sequences. ISRE, interferon-stimulated response element; Elk1, member of Ets oncogene
family; Tax/CREB, CREB family member; ATF2, activating transcription factor 2, CREB family. B, predicted transcription factor-binding sites of MAO-A upstream
sequences. Sp1/KLF, specificity protein1/Kruppel-like factor; GATA2, GATA-binding protein 2; TBP, TATA-binding protein; SRY, sex regulatory gene on chromosome Y;
GRE1, -2, and -3, glucocorticoid response elements 1–3. Transcription factor-binding sites are predicted by Genomatix (www.genomatix.de). Upstream sequences for
15-LO, ⫺2688 to ⫺1; upstream sequences for MAO-A, ⫺2000 to ⫺1. ATG ⫽ ⫹1 to ⫹3. Human monocytes (5 ⫻ 106/group) (C, D, and E) were either untreated or directly
stimulated with IL-13 (2 nM) for 1 h. To measure the binding of Stat1 (C), Stat3 (D), and Stat6 (E) to their cognate DNA-binding sequence present in the 15-LO promoter,
5 g of nuclear extracts/well were run in triplicate to detect activated Stat1, Stat3, and Stat6 using a TransAMTM Stat family kit. StatX BS-15LO, Stat6 BS-15LO, and StatX
BSC-15LO were used as competitors, whereas StatX BS MT-15LO was used as a noncompetitor (see “Results” and “Experimental procedures”). All the competitors and
noncompetitors were used at a concentration of 20 pmol/well. Nuclear extracts from IFN␥-stimulated COS-7 cells and IL-6 –stimulated HepG2 cells were used as
positive controls for activated Stat1 (C) and Stat3 (D), respectively. The wild-type (WT) and mutated (MT) consensus oligonucleotides were used to monitor the
specificity of the assay. The results are representative of three independent experiments. Data are the mean ⫾ S.D. (n ⫽ 3). Significant differences were determined by
comparing each group to the IL-13–treated monocytes as the control (*, p ⬍ 0.003 in C, and *, p ⬍ 0.002 in D and E).

epithelial cancer cells, MAO-A is already overexpressed, and no
further IL-13– dependent induction mechanism exists in these
cells.
We also examined NHBE cells for the co-induction of 15-LO
and MAO-A in response to IL-13 stimulation. Our results are
shown in Fig. 2, C–F, and they reveal that after 72 h of incubation with IL-13, 15-LO, and MAO-A, genes are co-induced in
NHBE cells at mRNA (Fig. 2, C and E) and at protein levels (Fig.
2, D and F), similar to our previous observations in primary
monocytes and in A549 lung carcinoma cells. These results
thus show the pathophysiological implication of the co-induction of 15-LO and MAO-A and further confirm that the local-
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ization of this phenomenon is not restricted only in immune or
cancer cells.
Stats (Stat1, Stat3, and Stat6) bind to their cognate sequences
derived from the 15-LO promoter in response to IL-13
treatment
As we demonstrated previously that Stat1, Stat3, and Stat6
are all required to control IL-13–mediated 15-LO and MAO-A
gene expression (1, 12), we next examined whether the Stats are
binding to both 15-LO and MAO-A promoter. To investigate
the binding of Stat transcription factors (Stat1, Stat3, and Stat6)
to their cognate DNA-binding sites present in the 15-LO pro-

Regulation of MAO-A in IL-13–activated cells
moter (Fig. 3A) after IL-13 stimulation, we performed competitive binding experiments using ELISA-based activation assays
for Stat1, Stat3, and Stat6. Our results indicated that the basal
level of binding activity of Stats (Stat1, Stat3, and Stat6) to their
consensus DNA-binding sequence was enhanced (⬃4-fold) by
IL-13 treatment (Fig. 3, C–E). StatX BS-15LO (oligonucleotides
corresponding to the cognate Stat-binding site (StatX binds
Stat1, Stat3, or Stat6) in the context of 15-LO promoter-flanking sequences) was used as a competitor in this assay and significantly inhibited the IL-13–induced DNA-binding activity of
Stat1 (Fig. 3C, *, p ⬍ 0.003), Stat3 (Fig. 3D, *, p ⬍ 0.002), and
Stat6 (Fig. 3E, *, p ⬍ 0.002). For competitive binding, Stat6
BS-15LO (oligonucleotides corresponding to one of the cognate Stat6-binding sites (⫺961) in the context of flanking
sequences present in the 15-LO promoter) was also added prior
to addition of the nuclear extract. Stat6 BS-15LO significantly
attenuated the IL-13–induced Stat6 DNA-binding activity (*,
p ⬍ 0.002) (Fig. 3E). StatX BSC-15LO (oligonucleotides containing the consensus Stat-binding site in the context of the
same flanking sequences present in StatX BS-15LO) was also
used as a competitor for comparison. Addition of StatX BSC15LO in this assay profoundly inhibited IL-13–stimulated
15-LO DNA-binding activity of Stat1, Stat3, and Stat6 (Fig. 3,
C–E). The wild-type (WT) consensus oligonucleotides also significantly reduced DNA-binding activity of Stat1, Stat3, and
Stat6 (Fig. 3, C–E). Conversely, StatX BS MT-15LO (a mutated
sequence of the cognate Stat-binding site in the context of the
same flanking sequences present in StatX BS-15LO) and the
MT consensus oligonucleotides were used as noncompetitors
in this assay and caused essentially no inhibition of IL-13–
induced DNA-binding activity of Stats (Stat1, Stat3, and Stat6)
(Fig. 3, C–E). These data show the direct binding of Stat transcription factors (Stat1, Stat3, and Stat6) to their cognate DNAbinding sites in the context of flanking sequences present in the
15-LO promoter after IL-13 stimulation in primary monocytes.
In contrast, our predicted transcription factor-binding sites
of MAO-A upstream sequences do not reveal any Stat consensus binding site in the MAO-A promoter but show the presence
of multiple Sp1-, GATA2-, TBP-, and GRE-binding sites (Fig.
3B). To justify and validate the prediction of different transcription factor-binding sites located in the MAO-A promoter, we
pursued a control experiment to determine whether the Sp1
transcription factor binds with the cognate binding sequence
present in the MAO-A promoter. Our results demonstrated
that the basal level of DNA-binding activity of Sp1 to the cognate binding sequence located in MAO-A gene promoter was
increased substantially in the presence of IL-13 (more than
4-fold) (Fig. S3). Sp1BS1-MAO-A and Sp1 BS2-MAO-A, oligonucleotides corresponding to the cognate Sp1-binding sites in
the context of MAO-A promoter flanking sequences, were used
as competitors in this assay, and significantly reduced the
IL-13–stimulated DNA-binding activity of Sp1 (Fig. S3, *, p ⬍
0.005). Sp1BS2C–MAO-A (oligonucleotides containing the
consensus Sp1-binding site in the context of the same flanking
sequences present in Sp1BS2–MAO-A) was also used as a competitor for comparison. Sp1BS2C–MAO-A significantly inhibited IL-13–induced DNA-binding activity of Sp1 (Fig. S3). The
wild-type (WT) consensus oligonucleotides also profoundly

inhibited Sp1 activation. In contrast, Sp1BS2 MT–MAO-A
(a mutated sequence of the cognate Sp1-binding site in the
context of the same flanking sequences present in Sp1BS2–
MAO-A) and the MT consensus oligonucleotides were used as
noncompetitors in this assay and showed no inhibitory effect
on IL-13–stimulated DNA-binding activity of Sp1 (Fig. S3).
These data thus validate our in silico predicted analysis and
present evidence that in response to IL-13 stimulation, Sp1
transcription factor directly binds to the cognate DNA-binding
sites (as predicted by our present analysis) in the MAO-A promoter after IL-13 stimulation in primary monocytes.
Egr-1 and CREB transcription factors regulate IL-13–activated
MAO-A gene expression in primary human monocytes
We previously demonstrated that in primary human monocytes Egr-1 (early growth response-1) and CREB specifically
bind to their cognate sequences located at the 15-LO promoter
in response to IL-13 stimulation (15). Our data provided further
evidence about the existence of two distinct bifurcating parallel
signaling pathways downstream of the IL-13 receptor that regulates 15-LO gene expression in primary monocytes (15). We
revealed that other than the canonical IL-4R␣–Jak2–Stat3-dependent pathway (14), there exists an IL-13R␣1–Tyk2-mediated pathway that is required for IL-13–induced Egr-1 and
CREB activation via MEK-ERK1/2 and thereby implicated
transcription factors Egr-1 and CREB as critical regulators of
IL-13–induced 15-LO gene expression in primary human
monocytes (15). As 15-LO and MAO-A genes are co-induced
upon exposure to IL-13 during alternative activation of monocytes, we further investigated the role of Egr-1 and CREB transcription factors in regulating IL-13–stimulated MAO-A gene
expression in primary monocytes. To show the impact of these
transcription factors on MAO-A gene expression, we transfected monocytes with decoy ODNs specific for Egr-1 and
CREB consensus sequences for 24 h and stimulated with IL-13
for an additional 24 or 48 h. We then determined the mRNA
and protein expression levels of MAO-A by comparing with
monocytes transfected with scrambled decoy ODN using
quantitative real time PCR and Western blot analysis (Fig.
S4, A and B).
As demonstrated in Fig. S4A, transfection of monocytes with
Egr-1 and CREB decoy ODNs significantly inhibited IL-13–
induced MAO-A mRNA expression levels as compared with
monocytes transfected with scrambled decoy ODN ( 44% for
Egr-1 and 59% for CREB). Co-transfection with a combination
of both Egr-1 and CREB decoy ODNs (2 M each) down-regulated MAO-A mRNA levels even further (85% inhibition with
the combination) as compared with the scrambled decoy ODNtransfected group. Transfection of monocytes in the absence of
the decoy ODNs (transfection control) as well as in the presence of the scrambled decoy ODNs followed by IL-13 stimulation showed very little effect on MAO-A protein expression
as compared with the nontransfected monocytes induced by
IL-13 (Fig. S4B). However, similar to the MAO-A mRNA, both
Egr-1 and CREB decoy ODNs individually attenuated IL-13–
activated MAO-A protein expression in a substantial manner
(Fig. S4B). Co-transfection of Egr-1 and CREB decoy ODNs (1
M each) also inhibited the IL-13–stimulated MAO-A protein
J. Biol. Chem. (2018) 293(36) 14040 –14064
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expression significantly as compared with scrambled decoy
ODN-transfected monocytes (Fig. S4B). We estimated the
effect of transfection of these decoys quantitatively as compared with scrambled decoy ODNs, and the results are represented in Fig. S4C. Our results reveal that transfection of the
Egr-1 decoy and CREB decoy inhibited IL-13–induced MAO-A
protein expression by ⬃35 and ⬃42%, whereas the combination of Egr-1 and CREB decoy ODNs (1 M each) reduced
IL-13–stimulated MAO-A protein expression by ⬃67% compared with the scrambled decoy ODN-transfected monocytes
(Fig. S4C). These data thus strongly support the regulatory role
of transcription factors Egr-1 and CREB in mediating IL13–stimulated MAO-A gene expression in primary monocytes
probably by inducing 15-LO expression.
Stats (Stat1, Stat3, and Stat6), Egr-1, and CREB transcription
factors are involved in maintaining MAO-A enzyme activity in
IL-13–stimulated monocytes
Earlier we showed that Stat1, Stat3, and Stat6 are all required
for 15-LO as well as MAO-A gene expression in alternatively
activated monocytes/macrophages by IL-13 (1, 12). We further
demonstrated that Egr-1 and CREB transcription factors also
regulate 15-LO (15) and MAO-A (Fig. S4) gene expression in
IL-13–activated monocytes. Here, we investigated the role of
these transcription factors in controlling the MAO-A enzyme
activity in monocytes after IL-13 stimulation. To examine that,
we transfected primary monocytes with the decoy ODNs of all
of these transcription factors along with the mismatch/scrambled decoy ODN controls followed by IL-13 stimulation, and we
then performed the native MAO-A enzyme activity assay. Our
results show that all the Stat decoys markedly attenuated
MAO-A enzymatic activity in IL-13–activated monocytes (*,
p ⬍ 0.002), whereas the mismatched ODNs of Stat1/Stat3 and
Stat6 scramble (used as controls) had very little effect on IL-13–
stimulated MAO-A enzyme activity (Fig. 4A). To check the
specificity of this assay, we treated monocytes with the MAOA–specific antisense or control sense ODNs before IL-13 stimulation. Treatment of MAO-A–specific antisense substantially
inhibited the MAO-A enzymatic activity, whereas the sense
control is without effect (Fig. 4A).
A similar experiment performed using Egr-1 and CREB
decoy ODNs again shows that these transcription factors also
down-regulated the IL-13–induced MAO-A activity both individually as well as in combination, whereas the scrambled decoy
ODNs had no effect (Fig. 4C). Here, the specificity of the enzymatic assay was also confirmed by using the MAO-A antisense
treatment (Fig. 4C). To examine the effectiveness of transfection using the decoy ODNs and mismatched/scrambled decoy
ODNS, we performed ELISA-based DNA-binding activity
assay of the transcription factors. Our results shown in Fig. 4, B
and D, demonstrate that decoy ODNs of the transcription factors (Stat1, Stat3, Stat6, Egr-1, and CREB) significantly reduce
the DNA-binding activity of the corresponding transcription
factors, whereas the mismatched/scrambled decoy ODNs have
no inhibitory effect compared with the transfection control
groups.
To check the transfection efficiency and equivalency across
multiple biological replicates using the decoy/mismatched
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decoy ODNs, we performed co-transfection experiments in
monocytes by mixing 2 g of pmaxGFP with each group containing 2 M Stat1 and Stat3 decoy ODNs or mismatched decoy
ODNs (as they are not tagged with a reporter of expression like
GFP). After the co-transfection, monocytes were kept in 10%
BCS/DMEM for 24 h and were observed under bright field and
fluorescence. From the results of this experiment (Fig. S5A), we
calculated the transfection efficiency for different biological
replicates, and our data show that the transfection efficiency for
different groups varies, ranging from a mean value of 46 –50%
(as presented in Fig. S5B). These data demonstrate more or less
an equivalent level of transfection across multiple biological
replicates. We further show evidence of approximately equal
levels of GFP expression in different groups as shown in Fig.
S5C.
Therefore, the results presented in Fig. 4 suggest that Stats
(Stat1, Stat3, and Stat6) as well as Egr-1 and CREB transcription
factors are critical regulators of MAO-A expression/enzyme
activity in alternatively activated monocytes by IL-13.
IL-13–induced MAO-A gene expression in alternatively
activated monocytes/macrophages and in A549 cells is
15-LO– dependent
As 15-LO and MAO-A are co-induced upon IL-13 exposure
in monocytes/macrophages and in A549 cells, and because
both of them are regulated by the transcriptional activation of
several Stats (Stat1, Stat3, and Stat6), Egr-1, and CREB in
the monocyte/macrophage system, we further investigated
whether one of them is the upstream regulator of another.
Hence, we treated monocytes with the activity inhibitors of
both 15-LO and MAO-A and assessed their effect on MAO-A
and 15-LO expression, respectively, at mRNA levels after IL-13
stimulation. Our results show that pretreatment with selective
15-LO activity inhibitor PD146176 reduces the mRNA expression of MAO-A in IL-13–activated monocytes significantly in a
dose-dependent manner, whereas pretreatment of monocytes
with MAO-A–specific inhibitor moclobemide has no inhibitory effect on IL-13–induced 15-LO mRNA levels (Fig, S6, A
and B). These results thus indicate 15-LO as the upstream regulator of MAO-A. To confirm the direct involvement of 15-LO
as the upstream regulator of MAO-A gene expression, we first
examined the effect of 15-LO antisense ODN on 15-LO expression at both the mRNA and protein level. Cells were treated
with the 15-LO–specific antisense or control sense ODN as
described earlier (41) and then stimulated with IL-13. Total
cellular RNA or proteins were extracted for real time RT-PCR
or Western blot analysis. Our results reveal that the 15-LO–
specific antisense ODN significantly inhibited both the IL-13–
induced 15-LO mRNA in A549 cells and in primary monocytes
(Fig. 5, A and C, respectively) (*, p ⬍ 0.005) and 15-LO protein
expression in monocytes (Fig. 5E), whereas the 15-LO sense
ODN showed no effect (Fig. 5, A, C, and E). To demonstrate the
direct involvement of 15-LO in IL-13–activated MAO-A gene
expression, monocytes were treated with 15-LO–specific antisense or sense ODNs and then stimulated with IL-13. IL-13–
induced MAO-A mRNA expression was significantly attenuated by 15-LO antisense ODN (*, p ⬍ 0.005) in both A549 cells
as well as in primary monocytes (Fig. 5, B and D, respectively),
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Figure 4. Stats (Stat1, Stat3, and Stat6), Egr-1, and CREB transcription factors regulate MAO-A activity via 15-LO expression in alternatively activated
monocytes/macrophages by IL-13. Monocytes (5 ⫻ 106/group) were either transfected with or without decoy or mismatched (Mis)/scrambled (Scr) decoy
ODNs to Stat3, Stat1, and Stat6 (A) or with 2 M scrambled, Egr-1, or CREB decoy ODNs or a combination of both Egr-1 and CREB decoy ODNs at 2 M (C) for 24 h
prior to the addition of IL-13 (A and C) for 48 h. In some groups, monocytes (5 ⫻ 106/group) were pre-treated with MAO-A sense (S) or antisense (AS) ODN (A and
C) and incubated with IL-13 (2 nM) for 48 h. A and C, native MAO-A enzyme activity was detected. In a total volume of 50 l, 20 l of whole-cell extract was
incubated with substrate (final concentration, 40 M) in the presence of MAO reaction buffer (100 mM HEPES (pH 7.5); 5% glycerol). After incubation at room
temperature for 3 h, 50 l of luciferin detection reagent was added, and the luminescent signal was measured after 20 min. To show the effect of decoy ODNs
of Stats (Stat1, Stat3, and Stat6), Egr-1, and CREB on IL-13–induced DNA-binding activity of the corresponding transcription factors, ELISA-based DNA-binding
activity assay was performed and represented in B and D. Data represented as mean ⫾ S.D.; (n ⫽ 3, *, p ⬍ 0.002). Data in A–D are from a representative of three
independent experiments.

whereas the 15-LO sense ODN showed no inhibitory effect.
Similar to MAO-A mRNA, MAO-A protein expression was
also checked after treatment with 15-LO antisense or sense
ODNs followed by incubation with IL-13. 15-LO antisense substantially inhibited the IL-13–induced expression of MAO-A
protein in primary monocytes, whereas 15-LO sense ODN had
no inhibitory effect (Fig. 5F). The effect of 15-LO antisense on
both the IL-13–stimulated expression of 15-LO and MAO-A
was further quantitatively determined and represented in Fig. 5,
G and H, respectively, based on the densitometric analysis of
the results shown in Fig. 5, E and F. Our data showed that 15-LO
antisense almost completely inhibited the expression of 15-LO

protein (Fig. 5G), whereas it reduced the expression of the
MAO-A protein level by ⬃70% compared with the IL-13–
treated control group (Fig. 5H). These results confirm that the
suppression of IL-13–stimulated 15-LO expression is directly
related with the down-regulation of MAO-A expression in
monocytes and in A549 cells. To further assess the specificity of
our antisense-based results, we checked whether any other
important marker during alternative activation of monocytes
by IL-13 is also attenuated by the treatment of 15-LO antisense
ODNs in monocytes. To investigate that, we analyzed the effect
of 15-LO–specific antisense ODN treatment on the expression of mannose receptor, a universal marker of alternative
J. Biol. Chem. (2018) 293(36) 14040 –14064
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Figure 5. 15-LO regulates IL-13–activated MAO-A gene expression in primary monocytes and in A549 cells. Primary monocytes and A549 cells (5 ⫻
106/group) were either pretreated with 15-LO antisense (AS) or sense (S) ODNs (5 M) (A–F) for 48 h followed by stimulation with IL-13 either for 24 h (mRNA)
or for 48 h (protein). A–D, total cellular RNA extracts were prepared and subjected to real-time PCR analysis. After normalization with GAPDH amplification, the
fold induction of 15-LO (A and C) and MAO-A (B and D) mRNA expression for different groups was plotted. Data are the mean ⫾ S.D. (n ⫽ 3). *, p ⬍ 0.005
compared with the IL-13–treated group. E and F, the post-nuclear extracts were separated by 8% SDS-PAGE and immunoblotted with 15-LO- (upper panel of
E) and MAO-A (upper panel of F)-specific antibodies. The same blots were stripped and reprobed with ␤-tubulin antibody to assess equal loading (lower panels
of E and F). The data shown represent one of three separate experiments giving similar results. G and H, the densitometric quantification of 15-LO and MAO-A
protein expression of monocytes was detected post-transfection with 15-LO sense (S) and antisense (AS) ODNs as indicated using ImageJ software. The data
were shown after normalization with the ␤-tubulin levels and represented in A.U., i.e. arbitrary units. Data are the means ⫾ S.E. and from three separate
experiments as mentioned earlier. Significant differences were determined by comparing the sense and antisense treated groups to the IL-13–treated control
(***, p ⬍ 0.001).

monocyte/macrophage activation (3, 42, 43). Primary monocytes were pretreated with 15-LO–specific antisense and sense
ODNs before stimulation with IL-13. After 5 days of incubation, the expression of the mannose receptor was evaluated by
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FACS analysis and was substantially increased by IL-13 stimulation (Fig. S6C), but the 15-LO–specific antisense ODN
showed no effect on IL-13–stimulated up-regulation of mannose receptor expression (Fig. S6C). These results thus confirm
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Figure 6. 15-LO is directly involved in regulating MAO-A enzyme activity in IL-13–stimulated A549 cells and primary monocytes/macrophages.
Monocytes and A549 cells (5 ⫻ 106/group) were either pre-treated with MAO-A and 15-LO sense (S) or antisense (AS) ODNs (A–D) and incubated with IL-13
(A–D) (2 nM) for 48 h or with the MAO inhibitors pargyline (1 M) and moclobemide (1 M) (A and C) for 30 min prior to stimulation with IL-13 (2 nM) (A and C)
for 48 h. A and C, native MAO-A enzyme activity was detected by MAO-GLO assay as described earlier. Data are represented as mean ⫾ S.D. (n ⫽ 3, *, p ⬍ 0.005).
B and D, A549 and primary monocyte lysates (50 g/well) were incubated with Amplex Red reagent/HRP/p-tyramine working solution for 60 min before the
fluorescence was measured. Data are represented as means ⫾ S.D.; (n ⫽ 3, *, p ⬍ 0.005). Data in all panels are from a representative of three independent
experiments.

the specificity of 15-LO–mediated regulation of MAO-A gene
expression in IL-13–activated monocytes.
Native MAO-A enzyme activity is also dependent on 15-LO in
IL-13–activated A549 cells and in primary
monocytes/macrophages
We further show that in addition to the direct involvement of
15-LO in regulating MAO-A expression in A549 cells and
in alternatively activated monocytes/macrophages by IL-13,
15-LO also directly controls MAO-A enzymatic activity in
IL-13–stimulated A549 cells and in monocytes/macrophages.
To determine the role of 15-LO on IL-13–induced MAO-A
activity in these cells, we adopted both MAO-GLO as well as
Amplex Red monoamine oxidase assay. We transfected A549
cells and monocytes both with MAO-A and 15-LO antisenses
along with their sense controls. In MAO-GLO assay we treated
the cells with IL-13 and performed the chemiluminescencebased assay using the manufacturer’s protocol. The results from
our assay show that both MAO-A- and 15-LO–specific anti-

sense ODNs significantly attenuated MAO-A enzyme activity
compared with IL-13–treated positive control, whereas their
sense ODN controls show no effect on MAO-A activity in
IL-13–activated A549 cells and in primary monocytes/macrophages (Fig. 6, A and C). In this assay we also included two
inhibitors of MAO enzyme activity. One is the pan-MAO inhibitor pargyline, and the other is MAO-A–specific inhibitor
moclobemide. Both these inhibitors substantially inhibited
the MAO-A enzymatic activity compared with the IL-13–
stimulated group (Fig. 6, A and C). These results thus confirmed
the specificity of the assay and demonstrated the role of 15-LO
in regulating MAO-A activity in IL-13–stimulated A549 cells as
well as in primary monocytes. To reconfirm our observation
by a second method, we did a similar experiment using the
Amplex Red assay of MAO-A. Our results further confirm that
both MAO-A and 15-LO antisenses markedly reduced IL-13–
mediated H2O2 generation in the presence of p-tyramine in
A549 cells and in monocytes/macrophages, whereas the sense
ODN controls showed no effect (Fig. 6, B and D). These results
J. Biol. Chem. (2018) 293(36) 14040 –14064
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unequivocally support that 15-LO directly regulates MAO-A
enzymatic activity in A549 cells and in primary monocytes/
macrophages in response to IL-13 stimulation.
IL-13– dependent expression of MAO-A in A549 and in primary
monocytes requires the involvement of PPAR␥
As 15-LO products HPODE/HPETE are well-known PPAR␥
ligands, we next explored the possibility that IL-13–induced
MAO-A gene expression in human monocyte/macrophage and
in A549 cells is mediated by coordinate induction of 15-LO and
PPAR␥. Hence, we investigated the probable involvement of
PPAR␥ and the mechanistic details associated with 15-LO–
mediated MAO-A expression in A549 as well as in primary
human monocytes in response to IL-13 stimulation. Our results
showed that the PPAR␥ antagonist GW9662 significantly
down-regulated the mRNA expression of MAO-A in IL-13–
activated A549 cells (Fig. 7A). A similar effect of GW9662 was
observed in primary monocytes where IL-13–induced MAO-A
mRNA expression is also reduced substantially by the addition
of GW9662 in a dose-dependent manner (Fig. 7C).
As we reported that the IL-13–activated MAO-A gene
expression depends on 15-LO and 15-LO generates the PPAR␥
ligand (13S)-HPODE and its stable form (13S)-HODE, we next
investigated the effect of addition of these fatty acids on the
restoration of MAO-A gene expression in those cells that are
already treated with the 15-LO antisense (followed by incubation with IL-13) to establish a direct role of PPAR␥ and its
ligand in IL-13–induced MAO-A expression. We already provided evidence that IL-13 induction of MAO-A mRNA expression was significantly reduced by the pre-treatment with a
selective 15-LO activity inhibitor PD146176 in monocytes in a
dose-dependent manner (Fig. S6A). Here, we further confirmed
this observation by the presence of 15-LO antisense ODN in
A549 cells (Fig. 7A) and in primary monocytes (Fig. 7B). Addition of the 15-LO product (13S)-HPODE at the indicated doses
restored MAO-A expression either in the presence of PPAR␥
antagonist GW9662 (Fig. 7A) or 15-LO AS ODN almost completely in IL-13–activated A549 cells (Fig. 7A). A similar restoration effect of MAO-A expression by (13S)-HPODE was also
observed in 15-LO AS-treated primary monocytes after IL-13
stimulation (Fig. 7B). (13S)-HODE demonstrated a similar
effect where it counteracted the effect of 15-LO AS after IL-13
activation in primary monocytes (Fig. 7B). To check the specificity of this experiment, we treated primary monocytes with the
MAO-A–specific antisense or control sense ODNs before IL-13
induction. Treatment of MAO-A–specific antisense significantly
reduced the MAO-A mRNA expression level, whereas the sense
control is without effect (Fig. 7B).
It was further shown that the PPAR␥ ligand (13S)-HPODE
successfully restored the effect of Stat6 decoy ODN on IL-13–
stimulated mRNA expression of MAO-A in primary monocytes (Fig. 7C), confirming that the involvement of PPAR␥ in
regulation of IL-13–induced MAO-A expression is also Stat6dependent. Furthermore, we demonstrate here that both (13S)HPODE and (13S)-HODE profoundly up-regulated the expression of MAO-A mRNA in A549 cells (Fig. 7A) and in primary
monocytes (Fig. 7C) even in the absence of IL-13. These results
thus show that 15-LO– dependent regulation of MAO-A
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expression in IL-13–activated cells is mediated by PPAR␥ and
that Stat6 might be involved in the PPAR␥-mediated regulation
of MAO-A gene expression. In addition, PPAR␥ is also involved
in regulating MAO-A expression in A549 cells and in primary
monocytes even in the absence of IL-13.
Stat6 directly interacts with PPAR␥ in IL-13–activated A549
cells
We next focused on resolving the intricate mechanisms associated with PPAR␥-mediated MAO-A gene transcription in
IL-13–stimulated cells. We first checked whether IL-13 treatment could enhance the expression level of PPAR␥. Our results
showed that IL-13 could not induce the expression of PPAR␥
protein, which was already present constitutively in A549 cells
(Fig. 8A). Our previous experiment, related to the involvement
of Stat6 in PPAR␥-mediated MAO-A gene expression, raised
the possibility of interaction between these two transcription
factors. Hence, we performed the co-immunoprecipitation (coIP) experiment in A549 lung epithelial carcinoma cells to show
that endogenously expressed PPAR␥ and Stat6 physically interact with each other after IL-13 administration for 5 h (this interaction can be seen even after 1 h of IL-13 treatment, data not
shown), and this association remains intact even after 5 days of
IL-13 incubation (Fig. 8B) when 15-LO and MAO-A induction
still persists in A549 cells (data not shown). As Stat6 is tyrosinephosphorylated even after 5 h of IL-13 exposure (Fig. S1F), we
next checked whether Stat6 in co-IPs is phosphorylated in
response to IL-13 treatment (for 5 h) by probing the co-immunoprecipitated sample with p-Tyr–Stat6 antibody. Our results
confirmed that Stat6 is in its tyrosine-phosphorylated (activated) form when it associates with PPAR␥ (Fig. 8C). In continuation of our Stat6 decoy ODN experiment, which showed
reduced expression of MAO-A mRNA (Fig. 7C), we further
performed the co-IP experiment after transfecting the A549
cells with Stat6 decoy ODN along with the Stat6 scrambled
ODN control to examine whether the Stat6 decoy ODN has any
effect on IL-13–induced PPAR␥-Stat6 association. Our results
demonstrate that in this competition experiment, endogenously present Stat6 interacts more with the Stat6 decoy ODNs
thereby less and less endogenous Stat6 is available for interaction with PPAR␥ (Fig. 8D), whereas Stat6 scrambled ODN has
no effect on PPAR␥–Stat6 interaction. These results thus show
that the interaction between Stat6 and PPAR␥ is necessary for
PPAR␥-mediated gene transcription in IL-13–activated cells.
Stat6 facilitates PPAR␥ activation and PPAR␥-mediated
MAO-A gene expression in response to IL-13 stimulation
We next investigated whether the interaction between Stat6
and PPAR␥ is required for PPAR␥ activation and PPAR␥-mediated MAO-A gene expression in IL-13–stimulated cells.
We discovered that IL-13 induced PPAR␥ activation (endogenous PPAR␥ DNA binding with its consensus DNA-binding
sequence) in A549 as well as in primary monocytes (Fig. 8, E and
F). In the presence of Stat6 decoy ODN, when the association
between PPAR␥ and Stat6 is diminished, PPAR␥ activation
(DNA-binding activity) was also significantly reduced compared with the IL-13–treated control group in both A549 cells
and in primary monocytes (Fig. 8, E and F), suggesting that

Regulation of MAO-A in IL-13–activated cells

Figure 7. 15-LO inhibitor and antisense as well as PPAR␥ antagonist block MAO-A expression in A549 cells and primary monocytes by IL-13, whereas
(13S)-HPODE and (13S)-HODE counteract the effect of PPAR␥ antagonist as well as 15-LO antisense. A549 cells and primary monocytes (5 ⫻ 106/group)
were either pretreated with 15-LO and MAO-A antisense (AS) or sense (S) ODNs (A and B) for 48 h or transfected with decoy or scrambled decoy ODNs to Stat6
(C) for 24 h followed by stimulation with IL-13 for 24 h (A–C). In some groups, (13S)-HPODE (20 M) and (13S)-HODE (20 M) were added either directly (for 24 h)
(A and C) or after 24 h of IL-13 incubation (HPODE and HODE addition in AS-treated group or in decoy ODN-treated group for 24 h) as shown in A–C. A and
C, A549 cells and monocytes were also pretreated with the PPAR␥ antagonist GW9662 (at indicated doses) for 30 min followed by stimulation with IL-13
for 24 h. In one group in A, (13S)-HPODE was added in GW9662-pretreated group after IL-13 incubation for 24 h and exposed for another 24 h. A–C, total
cellular RNA extracts were prepared and subjected to quantitative real-time PCR analysis. After normalization with GAPDH amplification, the fold
induction of MAO-A mRNA expression for different groups was plotted. Values are mean ⫾ S.E. of three separate experiments. *, p ⬍ 0.05 compared with
the IL-13–treated group.
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Figure 8. IL-13–induced PPAR␥ activation and MAO-A gene expression depends on Stat6. A549 cells (5 ⫻ 106/group) were either left untreated or treated
with IL-13 for 5 h. Cell lysates (total) were assessed for PPAR␥ protein expression level by Western blot analysis (upper panel of A). The same blot was then
stripped and reprobed with PKC␦ antibody to show equal loading (lower panel of A). B and C, physical interaction between Stat6 and PPAR␥ was investigated
by immunoprecipitation (IP) assay. A549 cells (5 ⫻ 106/group) were either left untreated or treated with IL-13 for 5 h (B and C) and 5 days (B). Cell lysates (total)
were immunoprecipitated with PPAR␥ antibody (B and C) followed by Western blot analysis using Stat6 (upper panel of B and middle panel of C) and phosphoTyr–Stat6 (upper panel of C) antibodies. Untreated (B and C) and IL-13–treated (C) A549 cell lysates (total) were run alongside as controls. The blots were then
stripped and reprobed with PPAR␥ antibody to assess equal loading of immunoprecipitated samples (lower panels of B and C). D, effect of Stat6 decoy ODN on
Stat6 and PPAR␥ association was studied by transfection of Stat6 scrambled and decoy ODNs into A549 cells (5 ⫻ 106/group) using PEI transfection reagent.
After 48 h post-transfection, IL-13 incubation was carried out for another 5 h. Cell lysates (total) were immunoprecipitated using PPAR␥ antibody and subjected
to immunoblot analysis using Stat6 antibody (upper panel of D). The same blot was then stripped and reprobed with PPAR␥ antibody to assess equal loading
(lower panel of D). E–G, A549 cells and monocytes (5 ⫻ 106/group) were either transfected with or without decoy or scrambled decoy ODNs to Stat6 (E, F, and
G) for 24 h followed by stimulation with IL-13 for 1 h (E and F) or for 48 h (G). Monocytes were also treated with either rosiglitazone (Rosi) or IL-13 (2 nM) for 1 h
or pretreated with indicated doses of PPAR␥ antagonist GW9662 for 30 min followed by stimulation with IL-13 for 1 h (E and F). E and F, nuclear extracts were
prepared, and 10 g of nuclear proteins were used to perform an immunodetection of activated PPAR␥ using a TransAMTM kit. The data are represented as
relative arbitrary units with rosiglitazone treatment set at 100. Data are represented as means ⫾ S.E. of three independent experiments giving similar results.
Significant differences were determined by comparing each group to the IL-13–treated A549 and monocytes as controls (*, p ⬍ 0.01). G, A549 cell lysates
(postnuclear) were separated by SDS-PAGE and immunoblotted with MAO-A (upper panel of G) antibody. The same blot was then stripped and reprobed with
␤-tubulin antibody (lower panel of G) to assess equal loading. Data in G are from a representative of three independent experiments showing similar results.

PPAR␥ DNA-binding activity depends on its interaction with
Stat6. In contrast, Stat6-scrambled ODN showed no inhibition.
As control for monitoring PPAR␥ DNA-binding activity, we
tested whether the PPAR␥ ligand rosiglitizone could induce
PPAR␥ activation and whether GW9662, the PPAR␥ antago-
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nist, could inhibit the IL-13–induced PPAR␥ activation. Our
results further demonstrate that PPAR␥ activation is enormously induced in the presence of rosiglitazone, whereas
GW9662 significantly blocked the IL-13–induced PPAR␥
DNA-binding activity (Fig. 8, E and F). To determine whether
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Stat6 –PPAR␥ interaction followed by PPAR␥ activation is critical for MAO-A gene expression in IL-13–activated cells, we
transfected A549 cells with both Stat6 decoy ODN or Stat6
scrambled ODN. Our data reveal that in presence of Stat6
decoy ODN, when the interaction between Stat6 and PPAR␥ is
significantly diminished and PPAR␥ DNA-binding activity is
markedly reduced, the IL-13–induced MAO-A protein and
mRNA expression is almost completely blocked compared with
the IL-13–treated positive control (Figs. 8G and 7C). In contrast, Stat6 scrambled ODN had no inhibitory effect. These
results thus suggest that Stat6 acts as a facilitator of PPAR␥
activation and PPAR␥-mediated regulation of MAO-A gene
expression in IL-13–activated cells.
IL-13– dependent MAO-A expression and activity are
regulated by PPAR␥ but do not require the involvement of
Stat6 and 15-LO in U937 monocytic cells
Although myeloid cell lines like U937 promonocytic cells are
highly proliferative and malignant cells have numerous differences from monocytes/macrophages, they are often used as an
experimental model for primary human monocytes. U937 cells
also have some technical advantages over human primary
monocytes or macrophages. For instance, their genetic background is homogeneous, which minimizes the degree of variability in the cell phenotype. Hence, U937 cells are widely used as
a model monocytic system in the laboratory for routine cell
biology experiments. Considering all these aspects, it is really
important to know whether the same control mechanism is
valid for IL-13–activated MAO-A gene expression in U937
promonocytic cells, which exist in primary monocytes and in
A549 cells.
Based on our preliminary data, which showed that 15-LO is
neither expressed, nor induced by IL-13 in U937 cells (Fig. 1I),
we predicted that 15-LO might not be involved in regulating
MAO-A expression and activity in U937 cells in response to
IL-13 stimulation. To conclusively determine the role of both
PPAR␥ and 15-LO, we carried out experiments using the
PPAR␥ antagonist GW9662 and 15-LO antisense ODN to
check the expression of MAO-A protein and mRNA in U937
cells after IL-13 stimulation. Although pretreatment of U937
cells with the PPAR␥ antagonist GW9662 abrogated IL-13–
induced MAO-A protein and mRNA expression, 15-LO antisense and Stat6 decoy ODN treatment showed no effect (data
not shown). We further used PPAR␥ ligand rosiglitazone and
(13S)-HPODE (15-LO product) to analyze whether they can
independently induce MAO-A expression in U937 cells. Our
results showed that both of them substantially enhanced the
level of MAO-A mRNA expression independent of IL-13
induction (data not shown).
Next, we checked the role of PPAR␥, Stat6, and 15-LO on
MAO-A enzymatic activity by performing the MAO-GLO
assay in U937 cells after transfecting the cells with decoy and
antisense ODNs followed by IL-13 stimulation. Our results
showed that Stat6 decoy ODN and 15-LO–specific antisense
ODN had no inhibitory effect on MAO-A enzyme activity. In
contrast, pretreatment of U937 cells with GW9662 showed
substantial inhibition on IL-13–induced MAO-A enzyme
activity (data not shown). From these results, we can conclude

that IL-13– dependent expression and activity of MAO-A in
U937 cells require PPAR␥ activation but are independent of
Stat6 and 15-LO expression/activity.
IL-13–stimulated migration of A549 tumor cells and primary
human monocytes is mediated by MAO-A and requires both
PPAR␥ and 15-LO activity
As we already demonstrated that IL-13–induced MAO-A
gene expression and activity in A549 lung epithelial carcinoma
cells and in primary monocytes are modulated by both PPAR␥
and 15-LO, we next wanted to investigate whether MAO-A–
mediated cellular function is also governed by these two critical
regulators. To evaluate the role of PPAR␥ and 15-LO on IL-13–
activated A549 cell migration mediated by MAO-A, we utilized
an in vitro transwell migration assay using the MAO-A activity inhibitor moclobemide along with the 15-LO inhibitor
PD146176 and PPAR␥ antagonist GW9662. In Fig. 9, A and B,
we first compared IL-13–induced A549 cell migration data
with metformin (8 mM)-treated A549 cells as positive control
(44). Next, we represented data in Fig. 9C, which suggest that
IL-13 treatment resulted in a significant enhancement of A549
cell migration compared with the untreated control. In the
presence of moclobemide, IL-13–induced A549 cell migration is reduced substantially, whereas moclobemide alone in
absence of IL-13 showed no change compared with the
unstimulated control (Fig. 9C), thereby suggesting a plausible
role of MAO-A in A549 tumor cell migration in vitro. Fig. 9D
represents microscopic images showing a significantly less
number of cells migrating following moclobemide treatment as
compared with IL-13–stimulated A549 cells.
Significant reduction of migration was also observed in
IL-13–activated A549 cells after treatment with the 15-LO
activity inhibitor PD146176 and PPAR␥ antagonist GW9662 in
a dose-dependent manner (Fig. 9, E and G) compared with
IL-13–stimulated positive control. Corresponding microscopic
images presented in Fig. 9, F and H, also showed that significantly fewer A549 cells migrated after PD146176 and GW9662
treatment with the indicated doses mentioned here as compared with IL-13–activated A549 cells. We further checked
whether the chemical inhibitors that are used for the experiments presented in Fig. 9 have any effect on cell viability at the
indicated doses. Our MTT assay data shown in Fig. S7, A–C,
suggest that the doses at which moclobemide, PD146176,
and GW9662 substantially reduced the migration of IL-13–
activated A549 cells have no inhibitory effect on the viability of
A549 cells for the stipulated time period. We also examined
whether inhibition of MAO-A activity by the specific inhibitor
moclobemide has any significant effect on A549 cell viability
and proliferation. Our additional experiments (trypan blue
exclusion assay and MTT assay) provide evidence that there is
no effect of the MAO-A inhibitor moclobemide (at 10 M dose)
on the A549 cell number as compared with IL-13–treated control (Fig. S7, D and E). These experiments thus act as control for
the potential effects of cell number on the migration observation as represented in Fig. 9C.
To establish the similar regulatory mechanisms for the
migration of IL-13–activated primary monocytes, we followed
the chemotaxis assay using a microchamber technique. Here,
J. Biol. Chem. (2018) 293(36) 14040 –14064
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Figure 9. Reduction of MAO-A, 15-LO, and PPAR␥ activity resulted in significant inhibition of IL-13–induced A549 cell migration. A549 cells were either
directly treated with IL-13 (2 nM) for 96 h (A) or pretreated with MAO-A inhibitor moclobemide, 15-LO–specific inhibitor PD146176, as well as PPAR␥ antagonist
GW9662 for 30 min followed by IL-13 treatment for 96 h (C, E, and G). A, metformin (8 mM) treatment of A549 cells (for 96 h) was considered as a positive control.
A, C, E, and G, in vitro transwell migration assay was performed. Briefly, 5 h after seeding 1.5 ⫻ 105 cells (in presence of serum free DMEM) in the upper chamber
of 12-well inserts, cells that migrated through the membrane of the transwell toward DMEM with 15% FBS were fixed and stained with Giemsa. Migrated cells
from six random fields were counted under microscope. Data were analyzed by one-way ANOVA (Dunnett test). A, C, E, and G, data are represented as mean ⫾
S.D. (n ⫽ 3, ***, p ⬍ 0.001; **, p ⬍ 0.01). Data in all panels are from a representative of three independent experiments showing similar results. Representative
microscopic images of migrated A549 cells in different inhibitor treated groups in presence and absence of IL-13 stimulation were also shown in B, D, F, and H,
respectively.

we also compared our migration data in primary human monocytes (after IL-13 incubation for 48 h) (Fig. 10A) with monocyte
migration in response to MCP-1 (50 ng/ml) for 90 min (45–47).
We then initiated our studies by using both the pharmacological inhibitor (moclobemide) as well as specific antisense ODN
against MAO-A. Our results suggest the involvement of
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MAO-A in regulating the migration of IL-13–activated
primary monocytes as both moclobemide (dose-dependently) and MAO-A antisense showed significant reduction of
migration of IL-13–stimulated monocytes, whereas MAO-A
sense ODN control is without effect (Fig. 10B). The role of
15-LO and PPAR␥ in MAO-A–mediated monocyte migration
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Figure 10. MAO-A and PPAR␥-mediated migration of IL-13–activated primary monocytes depend on 15-LO expression/activity. Primary human
monocytes (5 ⫻ 106/group) were either directly treated with IL-13 (2 nM) for 48 h (A) or pre-treated with sense and antisense ODNs to MAO-A (B) and 15-LO (C),
decoy and scrambled decoy ODNs to Stat6 (D) or with the MAO-A and 15-LO inhibitors, moclobemide (B) and PD146176 (C) at indicated doses for 30 min prior
to stimulation with IL-13 (2 nM) for 48 h. Cells were also pretreated with indicated doses of PPAR␥ antagonist GW9662 for 30 min followed by IL-13 stimulation
for 48 h (D). In some groups, (13S)-HPODE was added after 48 h of IL-13 incubation (HPODE addition in 15-LO AS-treated group for 24 h, C). A, monocyte
migration in response to MCP-1 (50 ng/ml) for 90 min was considered as a positive control. A–D, monocyte chemotaxis across a polycarbonate filter in response
to 15% FBS in DMEM was then measured as described earlier. All experiments were performed in triplicate. The results are expressed as the mean number of
migrated monocytes in five high-power fields ⫾ S.D. (⫻400 light microscope) and are representative of three similar experiments. *, p ⬍ 0.05; **, p ⬍ 0.005
(compared with the IL-13–treated group) from one-way ANOVA. Data in all panels are from a representative of three independent experiments showing similar
results.

was further assessed by using both 15-LO activity inhibitor
PD146176 as well as 15-LO–specific antisense ODN and
PPAR␥ antagonist GW9662. We demonstrated that PD146176
and 15-LO antisense ODN both markedly abrogated the ability
of IL-13–activated monocyte migration, whereas the 15-LO
sense ODN control had no effect (Fig. 10C). We further showed
that the PPAR␥ ligand (13S)-HPODE could restore the effect of
15-LO antisense ODN on monocyte migration (Fig. 10C). In
Fig. 10D, we provided evidence that PPAR␥ antagonist
GW9662 significantly inhibited the IL-13–stimulated monocyte migration in a dose-dependent way. Furthermore, our
results reveal that Stat6 decoy ODN also blocked the migration
of primary monocytes at a substantial level after IL-13 stimulation, whereas the Stat6 scrambled ODN showed no effect (Fig.
10D). Altogether, these results confirm the requirement of
PPAR␥ and 15-LO activity/expression in MAO-A–mediated
migration of IL-13–activated primary monocytes.
MAO-A–mediated ROS generation in presence of tyramine
requires both PPAR␥ and 15-LO activity/expression in
IL-13–activated A549 cells and in monocytes
Previously, we reported that generation of intracellular
ROS during the oxidation of biogenic amine-like tyramine by
MAO-A in alternatively activated monocytes/macrophages by

IL-13 (1). In this report, we continued this study and investigated the mechanistic details of the MAO-A–mediated ROS
generation in IL-13–activated monocytes and other cells in the
presence of tyramine. As a control, we first showed that moclobemide (a specific inhibitor for MAO-A) strongly inhibited the
tyramine induction of intracellular ROS generation in IL-13–
activated A549 cells and in primary monocytes (Fig. 11, A and
B). Furthermore, the involvement of both PPAR␥ as well as
15-LO in controlling MAO-A–mediated ROS generation was
also examined in A549 cells and in primary monocytes after
IL-13 induction. Our results produced evidence that the 15-LO
activity inhibitor PD146176 and antisense ODN against 15-LO
both significantly blocked the tyramine-induced enhancement
of intracellular ROS generation in IL-13–stimulated A549 and
in primary monocytes (Fig. 11, A and B), whereas the sense
ODN control for 15-LO had no effect. Moreover, (13S)HPODE, the 15-LO product that also acts as a ligand of PPAR␥,
rescued back the effect of 15-LO antisense ODN on MAO-A–
mediated ROS generation in IL-13–stimulated cells (Fig. 11, A
and B). The PPAR␥ antagonist GW9662 also executed a strong
reduction of ROS generation during tyramine oxidation of
MAO-A in IL-13–activated A549 cells and in monocytes/
macrophages (Fig. 11, A and B). In the presence of Stat6 decoy
J. Biol. Chem. (2018) 293(36) 14040 –14064
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Figure 11. Tyramine-induced ROS generation is regulated by 15-LO in
IL-13–activated A549 cells and in human monocytes/macrophages. A549
cells and primary human monocytes (5 ⫻ 106/group) were pre-treated with
sense and antisense ODNs to 15-LO (A and B), decoy, and scrambled decoy
ODNs to Stat6 (B) or with the MAO-A and 15-LO inhibitors, moclobemide (1
M) and PD146176 (5 M) (A and B) for 30 min prior to stimulation with IL-13
(2 nM) for 24 h. All type of cells were also pretreated with 5 M GW9662 for 30
min followed by IL-13 stimulation for 24 h (A and B). In some groups in A and
B, (13S)-HPODE (20 M) was added after 24 h of IL-13 incubation (HPODE
addition in AS-treated group for 24 h). A and B, cells were stimulated by tyramine (5 M) for 30 min and then incubated with the fluorescent probe
H2DCFDA (5 M) for another 30 min before the fluorescence was measured.
Data in A and B are expressed as percentage of unstimulated controls and
represented as means ⫾ S.D.; (n ⫽ 3, *, p ⬍ 0.005). Data are from a representative of three independent experiments.

ODN, again the function of MAO-A is controlled as evidenced
by the significant attenuation of ROS generation level in IL-13–
activated monocytes/macrophages, whereas Stat6-scrambled
ODN had no effect (Fig. 11B).
Altogether, these data strongly suggest that IL-13 signal
transduction uses a distinct 15-LO and PPAR␥-dependent
mechanism that is regulated by Stat6 in A549 cells and in primary monocytes/macrophages to control the IL-13– driven
function of MAO-A in tyramine-induced ROS generation.

Discussion
In this study, we demonstrated that during IL-13 stimulation
15-lipoxygenase and MAO-A are the two strongly up-regulated
genes that are co-induced in primary monocytes/macrophages,
A549 lung carcinoma cells, and in normal human bronchial
epithelial (NHBE) cells. In contrast, MAO-A is induced in the
human promyelomonocytic cell line, U937, by IL-13 stimulation independent of 15-lipoxygenase induction. Considering
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the role of MAO-A in the resolution of inflammation and its
other pathophysiological implications (48), it is an extremely
important requirement to carry out a detailed investigation to
understand the regulatory mechanisms associated with the
expression and function of MAO-A during IL-13 activation of
primary monocyte/macrophages, A549 lung carcinoma cells,
and in U937 promonocytic cells, which is also the primary focus
of this study. The outcome of this study, however, shows that
IL-13 induction of MAO-A has a major contribution in the
resolution of inflammation (in monocyte/macrophage system)
and in enhancement of the metastatic potential of cancer cells
(in A549 lung cancer).
Our investigations further suggest that in many other cancer
cells like in H1299 NSCLC (Fig. 2, A and B), in HCT116 colorectal cancer cells, or in PC3 prostate cancer cells (data not
shown), MAO-A is constitutively overexpressed, and IL-13 is
not involved in the further induction of MAO-A in these cells.
The discrepancies between the observations in H1299, NSCLC,
HCT116, and PC3 cells on the one hand and in A549 and NHBE
cells on the other hand can be explained by the fact that in
H1299, HCT116, or in PC3 cells, the relative expression level of
the decoy receptor (IL-13R␣2) is probably very high compared
with the IL-13R␣1 component that may affect the normal IL-13
signaling. In contrast, in A549 or in NHBE cells, the case may be
just reverse which promotes the normal IL-13 signaling leading
to the induction of both 15-LO and MAO-A genes in a concordant manner. The new observations in NHBE cells (Fig. 2, C–F)
also show that the signaling module to be investigated is not
restricted only in primary monocytes/macrophages and A549
lung carcinoma cells, and they bring more impact of our findings in other pathophysiological processes like asthma.
Our findings regarding the co-induction of MAO-A and
15-LO in IL-13–activated peripheral blood monocytes and
in A549 cells suggest a common regulatory pathway for the
expression of these two genes. Previously, we provided evidence for the involvement of the same Jaks and Stats in regulating MAO-A gene expression that are required for 15-LO gene
expression in IL-13–activated monocytes (1). Here, we further
demonstrate that Egr1 and CREB, the two crucial transcription factors that control 15-LO gene expression (15), are also
involved in regulating MAO-A gene expression. Furthermore,
based on the in silico promoter analysis studies, we speculated
the existence of Stats (Stat1, Stat3, and Stat6), Egr-1, and CREBbinding sites located in the promoter of the 15-LO gene and
validated our predictions by performing experiments that
showed the direct binding of Stats (Stat1, Stat3, and Stat6),
Egr1, and CREB transcription factors to their cognate DNAbinding sites in the context of flanking sequences present in the
15-LO promoter (this study and see Ref. 15). All these observations led us to speculate that the promoter of the MAO-A gene
may also contain the cognate sequences for the binding of the
same transcription factors. Although our in silico structural
promoter analysis failed to detect any Stat, Egr-1, or CREBresponsive sequences in the 5⬘-flanking region of MAO-A gene
promoter (this study), the discrepancies between these observations can be explained by the fact that these transcription
factors may not be directly involved in regulating MAO-A gene
expression. This hypothesis is directly supported by the obser-
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vation in this study that 15-LO antisense oligonucleotide
transfection significantly inhibits IL-13–induced MAO-A gene
expression in primary human monocytes and in A549 cells. We
provide evidence for the first time that in case of primary monocytes/macrophages, the MAO-A gene expression and activity
are directly regulated by 15-LO, which is specifically co-induced during the alternative activation of monocytes/macrophages by IL-13 (no induction of MAO-A or 15-LO during
conventional activation by LPS or IFN␥), and has a considerable
impact in the resolution of inflammation.
We explored the regulatory mechanisms that control the
expression/activity and function of MAO-A, a crucial marker of
alternative activation of primary monocytes. Our investigation
reveals the existence of several regulatory pathways that are all
PPAR␥-dependent but either 15-LO– dependent or -independent during IL-13 activation. In primary monocyte/macrophages and in A549 cells, 15-LO is co-induced with MAO-A by
IL-13 stimulation due to the presence of an unmethylated
15-LO promoter in these cellular systems. In contrast, the
15-LO promoter is exclusively methylated in U937 cells and
thereby incapable of expressing the 15-LO gene after IL-13 activation (49). Hence, the IL-13–induced MAO-A gene expression/function is independent of 15-LO in U937 cells.
PPAR␥ is a lipid-activated transcription factor regulating cellular lipid metabolism and inflammation (50 –53). Requirement of PPAR␥ activity for alternative activation of macrophages is already reported (54, 55). Although alternative
activation of macrophages by IL-4/IL-13 is linked with PPAR␥mediated transcriptional regulation, the detailed mechanism of
this process has yet to be explored. Moreover, it is also documented that the IL-4 –Stat6 –PPAR␥ signaling axis is crucial for
the differentiation of monocytes into alternatively activated
macrophages and for innate immune responses (53, 56). Further studies demonstrated PPAR␥ as a downstream effector of
IL-4 signaling rather than a direct regulator of alternative
activation of the monocyte/macrophage system (53, 56). During induction of 15-LO gene expression, 15-LO metabolites
15-HPETE/13-HPODE can act as potential ligands of PPAR␥,
which control the PPAR␥-dependent gene expression. Moreover, our results in this study further suggest that Stat6, by
interacting with PPAR␥, promotes PPAR␥’s DNA binding
and finally facilitates the PPAR␥-mediated gene expression in
IL-13–activated cells. The cross-talk between the two transcription factors (Stat6 and PPAR␥) to orchestrate the gene
expression during IL-13 activation is not unprecedented and is
previously reported between other transcription factors (57,
58), but the molecular details of this cross-talk remain to be
determined and definitely need further study and clarification. Thus IL-13–Stat6 –15-LO–PPAR␥ axis may have considerable effect for monocyte/macrophage physiology and
function during alternative activation and also on the resolution of inflammation.
Although the promyelomonocytic cell U937 is considered as
the experimental model system for monocytes and is extensively used to carry out many in vitro experiments due to the
stability, consistency, and reproducibility of the system, the
promonocytic U937 cells cannot be considered as an appropriate model in the context of a real life situation. Based on the

differential regulation of IL-13–induced MAO-A expression
and function between mature monocytes/macrophages and
U937 promonocytes, primary monocytes represent the correct model system for the analysis of IL-13 activation of
monocytes/macrophages.
Mature monocytes migrate toward sites of inflammation and
infection where they differentiate into inflammatory macrophages or into dendritic cells. Monocyte migration into sites of
inflammation is a crucial event for the pathogenesis of inflammatory and degenerative diseases. The mechanisms that control monocyte/macrophage trafficking under infectious and
inflammatory conditions have not been fully elucidated. Our
data presented in this study clearly show that MAO-A is a critical regulator of monocyte migration in IL-13–stimulated cells.
This is the first report that provides strong evidence about the
role of MAO-A in monocyte/macrophage chemotaxis. In addition, our data also establish the fact that in primary monocytes
15-LO–PPAR␥–MAO-A signaling axis is involved in regulating monocyte migration after IL-13 stimulation.
In cancer cells, migration and invasion are the initial steps
that control metastasis, which is a predominant cause of
cancer-related death. Recent reports reveal that MAO-A is
involved in promoting prostate cancer progression by inducing
epithelial to mesenchymal transition (EMT), which ultimately
causes elevation of ROS, thus enhancing the ability of migration
and invasion of these cells (39, 59). MAO-A enzymatic activity
is shown to be the main cause of MAO-A– driven ROS generation in cancer cells, which acts as the critical regulator of
MAO-A–mediated functions like migration, invasion, and proliferation (39, 59, 60). A recent report also suggests that IL-13
induces EMT phenotype in colorectal cancer cells by promoting migration and invasion of these cells via Stat6 activation
(61). In an attempt to find out whether IL-13–induced MAO-A
is involved in enhancing the aggressiveness of different types of
cancer cells, we exposed different cancer cells to IL-13. We
found that in many cases MAO-A is already constitutively present in these cells (not induced by IL-13 incubation) and promoting migration and invasion of these cells.5 A549 lung carcinoma cell is the unique cell type among the cancer cells where
IL-13 induces MAO-A gene expression that causes increased
migration and invasion (data not shown) and thereby enhances
the metastatic potential of the lung cancer cells. Hence, these
data in general propose that MAO-A is an important mediator
of cancer metastasis. Our study also demonstrates for the first
time that reactive oxygen species (ROS) are generated by
MAO-A in IL-13–activated A549 lung epithelial carcinoma
cells. As the MAO-A–mediated ROS generation is believed to
have significant influence on A549 cell migration and cellular
proliferation, we are interested in exploring the mechanistic
details of this process in IL-13–activated A549 lung carcinoma
cells. Furthermore, targeting MAO-A and disrupting its downstream signaling pathways may provide a promising therapeutic intervention in the pathogenesis of lung cancer.
In summary, we have uncovered the underlying mechanisms
associated with MAO-A expression, activity, and function in
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Figure 12. Schematic diagram showing the proposed mechanism of
IL-13–induced MAO-A expression in primary human monocytes and
A549 lung epithelial cancer cells.

IL-13–activated cells. Our results show the existence of IL13– dependent and 15-LO– dependent regulation of MAO-A
expression/activity in both primary human monocytes and in
A549 lung epithelial carcinoma cells and clearly show the presence of an IL-13 ⬎ STAT6 ⬎ 15-LO ⬎ PPAR␥ ⬎ MAO-A
signaling cascade (Fig. 12), which ultimately governs the function of MAO-A, a critical enzyme involved in the resolution of
inflammation and in the progression of cancer. In contrast, we
provide evidence that IL-13– dependent but 15-LO–independent regulation of MAO-A expression/activity is operating in
U937 monocytic cells. In the first case, endogenously produced
15-LO metabolite ((13S)-HPODE) can act as a ligand of PPAR␥
and control the PPAR␥-mediated gene transcription. In the
second case, IL-13 stimulation can lead to activation of PPAR␥
by other ligands (other than (13S)-HPODE) and facilitate
MAO-A gene transcription. In the absence of IL-13, exogenously added (13S)-HPODE can activate PPAR␥ in all these cell
types and further induce MAO-A gene expression/activity and
function. We further demonstrate the inductive and cooperative relationship between Stat6 and PPAR␥ in IL-13– dependent regulation of MAO-A expression/activity and function in
both monocytes and A549 cells where Stat6 interacts with
PPAR␥ and acts as a positive regulator of PPAR␥-mediated
gene transcription (Fig. 12). The salient features of our study
are the result of MAO-A expression/activity being directly
involved in the migration and tyramine-induced ROS generation in primary monocytes and A549 lung cancer cells. These
studies have major implications for understanding the mechanism and function of alternatively activated monocytes/macrophages by IL-13 and add novel insights into the pathogenesis
and potential treatment of different inflammatory diseases.
Our results further indicate the probable contribution of
MAO-A in lung cancer metastasis and suggest the potential of
MAO-A as a therapeutic target in lung cancer.
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Experimental procedures
Reagents
Recombinant human IL-13 and IFN-␥ were purchased from
BIOSOURCE and Invitrogen. The 15-LO standard and the rabbit reticulocyte 15-LO antibody, cross-reacting with human
15-LO, were raised in sheep and obtained as a gift from Dr.
Joseph Cornicelli (Molecular Imaging). The other primary antibodies used in this study were as follows: MAO-A, PKC␦,
PPAR␥, and ␤-tubulin from Santa Cruz Biotechnology (Santa
Cruz, CA). Antibody to Stat6 was purchased from Pharmingen.
Anti-phosphotyrosine-Stat6 (pTyr-641–Stat6) antibody was
purchased from Cell Signaling Technology (Beverly, MA). ChemoTx Disposable Chemotaxis System (catalog no. 106-5) was
purchased from Neuro Probe, Inc. (Gaithersburg, MD), and
Hema 3 stain set (catalog no. 122-911) was from ThermoFisher
Scientific (Pittsburgh, PA). The ROS-sensitive fluorescent
probe 6-carboxy-2⬘,7⬘-dichlorodihydrofluorescein diacetate,
diacetoxymethyl ester (H2DCFDA), was from Life Technologies, Inc. Amplex Red monoamine oxidase assay kit (catalog no.
A12214) was from Molecular Probes (Invitrogen). MAOGLOTM assay kit (catalog no. V1401) and MAO-A enzyme
(human recombinant enzyme expressed in Yeast, catalog no.
V1452) were purchased from Promega (Madison, WI). Polyethyleneimine (PEI) transfection reagent was also obtained as a
kind gift from Dr. Mahadeb Pal, Bose Institute, India. LPS,
Tyramine and pharmacological inhibitors such as pargyline (a
pan-MAO inhibitor) and moclobemide (specific inhibitor for
MAO-A) were purchased from Sigma. Rosiglitazone, GW9662,
PD146176, (13S)-HPODE, and (13S)-HODE were from Cayman Chemical (Ann Arbor, MI). The inhibitors were stored
either at room temperature or at ⫺20 °C as concentrated stock
solutions (either in water or DMSO) according to the manufacturer’s instructions.
Ethics statement
All studies involving human subjects were approved by the
Institutional Ethical Committee For Human Research, National
Institute Of Technology, Durgapur, West Bengal, India. These
studies abide by the Declaration of Helsinki principles.
Cell culture
A549 (human lung adenocarcinoma), H1299 (nonsmall cell
lung cancer cell), and U937 (leukemic monocytic lymphoma)
cells were procured from the central cell repository of the
National Center for Cell Science (NCCS), Pune, India. The
A549 and H1299 lung cancer cell lines were cultured in complete DMEM supplemented with 4.5 mg/ml glucose and other
ingredients containing 10% FBS, 1 mM sodium pyruvate, 2 mM
L-glutamine, nonessential amino acids, 100 units/ml penicillin,
100 g/ml streptomycin, and 50 g/ml gentamycin sulfate at
37 °C with 5% CO2. U937 cells were cultured in RPMI 1640
medium (pH 6.8). Media were supplemented with 10% FBS and
antibiotics containing 50 IU/ml penicillin G and 50 g/ml
streptomycin. The cells were incubated at 37 °C in a humidified
atmosphere containing 5% CO2 and subcultured every 72 h
using an inoculum of 5 ⫻ 105 cells/ml. NHBE cells were cultured under air-liquid interface (ALI) as described previously
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(62, 63). Cultures were grown at ALI for 12 days before the
media were removed and replaced with media containing 2 nM
(30 ng/ml) IL-13 and incubated for 72 h. Cells were tested and
authenticated periodically and before each experiment both by
monitoring cellular morphology at regular intervals by comparative microscopic observation using both high and low culture
densities and by evaluating cellular growth analysis by checking
proliferation and growth by standard MTT assay.
Isolation of human monocytes
Human peripheral blood monocytes (PBM) were isolated
either by separation of mononuclear cells followed by adherence to BCS-coated flasks (40) or by Ficoll-Hypaque sedimentation followed by countercurrent centrifugal elutriation (64,
65). PBM purified by these two methods were identical in
response to IL-13 and consistently ⬎95% CD14⫹. These studies
complied with all relevant guidelines and institutional policies
regarding the use of human subjects.
Immunoprecipitation and immunoblotting
PBM were routinely treated with IL-13 (2 nM) for various
time intervals. (This dose was chosen because it demonstrated
comparable 15-LO induction in monocytes in numerous previous studies performed by our group.) Total and postnuclear
extracts were prepared by previously published protocols (11,
66). After determining the protein concentration using the
Bradford reagent from Sigma (catalog no. B6916), lysate proteins (50 g/well) were resolved by 8 –10% SDS-PAGE and subjected to immunoblotting as described previously (15). 15-LO
protein was detected on Western blottings following a previously described protocol (40). Immunoprecipitation experiments were performed according to our previously published
method (14) using prewashed Sepharose-protein G beads (20 –50
l of packed beads per volume/ml of extract) (Roche Diagnostics,
Mannheim, Germany) at 4 °C overnight. The beads were washed
three times with lysis buffer, and the immune complexes were
collected. Immune complexes were released by boiling the beads
in SDS sample buffer and were then subjected to Western blot
analysis as described above. Immunoblots were stripped and reprobed to assess equal loading according to our previously published protocol (11).
RNA extraction and real-time RT-PCR
Monocytes (5 ⫻ 106 in 2 ml of 10% BCS/DMEM) were plated
in six-well culture plates, treated with antisense or decoy ODN,
and followed by treatment with IL-13 (2 nM) for 24 h. A549 and
U937 cells were also treated similarly with the ODNs and incubated with IL-13 for the same time. In some groups, cells were
directly treated with (13S)-HPODE/(13S)-HODE for the stipulated time period. Total cellular RNA was extracted using the
RNeasy mini kit from Qiagen (Valencia, CA), and real-time
quantitative RT-PCR was performed according to established
protocol (12). The sequences of the primers used were as
follows: 15-LO forward 5⬘-GCTGGAAGGATCTAGATGACT-3⬘ and 15-LO reverse 5⬘-TGGCTACAGAGAATGACGTTG-3⬘; MAO-A forward 5⬘-GCCAAGATTCACTTCAGACCAGAG-3⬘ and MAO-A reverse 5⬘-TGCTCCTCACACCAGTTCTTCTC-3⬘. GAPDH was used as an internal control

with the primer sequences of forward 5⬘-CACCAACTGCTTAGCACCCC-3⬘ and reverse 5⬘-TGGTCATGAGTCCTTCCACG-3⬘. 15-LO and MAO-A gene expression in primary monocytes and different cell lines were assessed by quantitative
RT-PCR using SYBR Green on a 7500 Fast Real-time PCR system (Applied Biosystem).
DNA-binding activity of Stat1, Stat3, and Stat6
A TransAMTM Stat family kit (Active Motif) was used to
evaluate the DNA-binding activity of Stat1, Stat3, and Stat6
according to the manufacturer’s instructions. Briefly, nuclear
extracts were incubated in a 96-well assay plate precoated with
immobilized
oligonucleotide containing the Stat consensus binding site (5⬘TTCCCGGAA-3⬘). The active forms of Stat1, Stat3, and Stat6
contained in nuclear extracts specifically bind the oligonucleotide. The wild-type (WT) consensus oligonucleotide was provided with the kit as a competitor for Stat binding to monitor
the specificity of the assay by preventing Stat binding to the
probe immobilized on the plate. Conversely, the mutated consensus oligonucleotide was provided as a control and was
expected to have a limited competition with the Stat consensus
binding site. The detection of activated Stats (Stat1, Stat3, and
Stat6) was carried out with specific Stat1 and Stat3 primary
antibodies (supplied by the kit) and Stat6 rabbit polyclonal antibody (from Pharmingen) and an HRP-conjugated secondary
antibody supplied in the kit. The detection of activated Stats
was carried out by monitoring the colorimetric readout at 450
nm with a reference wavelength of 655 nm using a SynergyTM
HT multimode microplate reader from Biotek. For competitive
binding experiments, different oligonucleotides corresponding
to the cognate Stat-binding sites (as predicted by Genomatix) in
the context of 15-LO promoter-flanking sequences (StatX
BS-15LO (oligonucleotides corresponding to the cognate Statbinding site; StatX binds Stat1, Stat3, or Stat6) and Stat6
BS-15LO (oligonucleotides corresponding to one of the cognate Stat6-binding sites)) were used in this assay. The singlestranded sequences of these competitor ODNs were as follows:
StatX BS-15LO sense, 5⬘-GAATGTACCTTCCTCAAATGCCAC-3⬘; Stat6 BS-15LO sense, 5⬘-AGACTTTCCTGAGAAACCGGAGGT-3⬘. As a control competitor, we used the consensus Stat-binding site in the context of the same flanking
sequences present in StatX BS-15LO (StatX BSC-15LO). The
sequence of the sense strand of this control competitor (StatX
BSC-15LO sense) was 5⬘-GAATGTACCTTCCCGGAATGCCAC-3⬘. As a noncompetitor, a mutated sequence of the cognate Stat-binding site in the context of the same flanking
sequences present in StatX BS-15LO (StatX BS MT-15LO) was
used in this assay. The sequence of the sense strand of this
noncompetitor (StatX BS MT-15LO) was 5⬘-GAATGTACCGACGGCAGATGCCAC-3⬘. All of these ODNs were purchased
from Integrated DNA Technologies (Coralville, IA).
ELISA to quantitate the DNA-binding activity of EGR1
A transcription factor ELISA kit from Panomics (Panomics,
Santa Clara, CA) was used to assess the binding activity of EGR1
according to the manufacturer’s instructions. In brief, activated
EGR1 molecules from nuclear extracts bound to an EGR1 conJ. Biol. Chem. (2018) 293(36) 14040 –14064
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sensus binding site (EGR1 probe, 5⬘-GCGGGGGCG-3⬘) on a
biotinylated oligonucleotide were immobilized on a streptavidin-coated 96-well assay plate. The EGR1, bound to the oligonucleotide, was detected by an antibody against EGR1, followed
by an HRP-conjugated secondary antibody reaction with the
TMB substrate to provide a colorimetric readout that was taken
at 450 nm.
TransAMTM CREB activation assay
A TransAMTM CREB kit from Active Motif (Carlsbad, CA)
was used to evaluate the cAMP-responsive element (CRE) promoter-binding activity of activated (phosphorylated) CREB
according to the manufacturer’s instructions. Nuclear extracts
were incubated in a 96-well assay plate precoated with immobilized oligonucleotide containing the CRE promoter site (5⬘TGACGTCA-3⬘). The detection of activated CREB was carried
out with a specific pCREB primary antibody (1:500 dilution in
1⫻ antibody binding buffer (supplied as a component by the
kit)) and an HRP-conjugated secondary antibody. After incubation with the developing solution for the recommended time,
the reaction was stopped, and the colorimetric readout was
taken at 450 nm.
DNA-binding activity of PPAR␥
A TransAMTM kit (Active Motif) was used to evaluate the
DNA-binding activity of PPAR␥ according to the manufacturer’s instructions. Briefly, nuclear extracts (10 g) were incubated in a 96-well assay plate precoated with immobilized
oligonucleotide containing the PPRE (5⬘-AACTAGGTCAAAGGTCA-3⬘). Activated PPAR␥ (after treatment with
rosiglitazone or IL-13) specifically binds the oligonucleotide.
The detection of activated PPAR␥ was carried out with a specific primary antibody and an HRP-conjugated secondary antibody supplied in the kit. The detection of activated PPAR␥ was
carried out by monitoring the colorimetric readout at 450 nm
with a reference wavelength of 655 nm using a SynergyTM HT
multimode microplate reader from Biotek. All the data shown
represent the amount of activated PPAR␥ in arbitrary units.
Monitoring of Sp1 DNA-binding
Monitoring of Sp1 activity was performed by an ELISA-based
assay using a TransAMTM kit (Active Motif) to evaluate the
DNA-binding capacity of Sp1 transcription factor according to
the manufacturer’s instructions. Briefly, nuclear extracts (5 g)
were incubated in a 96-well assay plate precoated with immobilized oligonucleotide containing the Sp1 consensus binding
site (5⬘-GGGGCGGGG-3⬘). Activated Sp1 (after treatment
with IL-13) specifically binds the oligonucleotide. The detection of activated Sp1 was carried out with a specific primary
antibody and an HRP-conjugated secondary antibody supplied
in the kit. The detection of activated Sp1 was carried out by
monitoring the colorimetric readout at 450 nm as described
earlier. For competitive binding experiments, different oligonucleotides corresponding to the cognate Sp1-binding sites (as
predicted by Genomatix) in the context of MAO-A promoter
flanking sequences (Sp1 BS1-MAO-A (oligonucleotides corresponding to the cognate Sp1-binding site 1 located in the
MAO-A promoter) and Sp1 BS2-MAO-A (oligonucleotides
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corresponding to another cognate Sp1-binding site 2 in the
MAO-A promoter)) were used in this assay. The singlestranded sequences of these competitor ODNs were as follows:
Sp1 BS1-MAO-A sense, 5⬘-AGCCCGGGGGCGGAGCCGATCCTT-3⬘; and Sp1 BS2-MAO-A sense, 5⬘-CGCCCAGGGGCGGAGCTGATGTTT-3⬘. As a control competitor, we used
the consensus Sp1-binding site in the context of the same flanking sequences present in Sp1 BS2-MAO-A (Sp1 BS2C-MAOA). The sequence of the sense strand of this control competitor
(Sp1 BS2C-MAO-A sense) was 5⬘-CGCCCAGGGGCGGGGCTGATGTTT-3⬘. As a noncompetitor, a mutated sequence
of the cognate Sp1-binding site in the context of the same flanking sequences present in Sp1 BS2-MAO-A (Sp1 BS2-MT–
MAO-A) was used in this assay. The sequence of the sense
strand of this noncompetitor was 5⬘-CGCCCATTGCCCAAGCTGATGTTT-3⬘. All of these ODNs were supplied by Integrated DNA Technologies.
Treatment of monocytes and A549 and U937 cells with 15-LO
and MAO-A antisense ODNs
15-LO antisense and sense ODNs were obtained from Invitrogen-Life Technologies, Inc., and handled according to the
manufacturer’s instructions. The 15-LO antisense ODN sequence
was 5⬘-CCTGCACAGAGATCCAGTTGC-3⬘. A complementary 15-LO sense ODN sequence was used as a control. 15-LO
antisense or sense ODNs (5 M) were boiled for 2–3 min and
then cooled at room temperature before being added to human
monocytes (5 ⫻ 106 in 2 ml of 10% BCS/DMEM) and A549 and
U937 cells. To check the effect of 15-LO antisense ODN on
15-LO protein expression, IL-13 (2 nM) was added to the appropriate samples 2 h after the antisense treatment. Cells were
allowed to incubate at 37 °C and were re-fed with 15-LO sense
and antisense ODNs (5 M) after 24 h. Cells were then harvested and assayed for silencing 48 h after 15-LO antisense
treatment. For real-time PCR experiments with the 15-LO antisense ODNs, cells were treated with 15-LO sense or antisense
ODNs (5 M) for a total period of 48 h with one re-feeding after
24 h prior to the stimulation with IL-13 for 24 h.
The sequences of the MAO-A antisense and sense ODNs are
as follows: MAO-A, antisense 5⬘-ATTTGTCAGCATGTTGAGCC-3⬘, and MAO-A sense, 5⬘-GGCTCAACATGCTGACAAAT-3⬘.
For MAO-A sense and antisense treatment, cells were pretreated with MAO-A sense or antisense (AS) ODN (10 M) for
2 h prior to IL-13 addition and then re-fed with 10 M ODNs
after 24 h and incubated for another 24 h before harvesting the
cells. For the transfection control, cells were incubated with the
transfection reagent alone for 48 h. All ODNs were end-modified (phosphorothioated, three bases at the 5⬘ and 3⬘ ends) to
limit DNA degradation, and all were HPLC-purified before use
(Invitrogen).
Transfection of Egr-1 and CREB decoy and scrambled decoy
ODNs into monocytes
Double-stranded decoy ODNs containing the conserved
promoter-binding site of the CREB, Egr-1, and a scrambled
sequence were prepared from complementary single-stranded
phosphorothioate-modified oligonucleotides ordered from
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Invitrogen by melting at 95 °C for 5 min, followed by a cooldown phase for overnight. Human monocytes (5 ⫻ 106 cells/
well in 2 ml of 10% BCS/DMEM) were plated in six-well culture
plates overnight. Cells were then transfected with decoy ODN
at a 2 M concentration as indicated with Superfect Transfection Reagent (Qiagen, Valencia, CA) according to the manufacturer’s instructions for 24 h. Monocytes were then incubated
in the absence or presence of 2 nM IL-13 for another 24 h for
MAO-A mRNA quantification or 48 h for MAO-A protein
detection. The single-stranded sequences of the decoy ODNs
were as follows: CREB (consensus): sense, 5⬘-AGAGATTGCCTGACGTCAGAGAGCTA-3⬘; Egr-1 (consensus): sense,
5⬘-CCCGGCGCGGGGGCGATTTCGAGTC-3⬘; scrambled:
sense, 5⬘-AACAGAAGCCAGGAACCCTCCTCT-3⬘, adapted
from Grote et al. (67).
Transfection of Stat1, Stat3, and Stat6 decoy and mismatched/
scrambled ODNs into primary monocytes and A549 cells
The phosphorothioated ODNs used for Stat1, Stat3, and
Stat6 decoys were purchased from Invitrogen. These decoys
were used in previous studies and shown to provide specific
inhibition of Stat1, Stat3, and Stat6 activities (12, 68). The
sequences for the decoys were 5⬘-ATATTCCTGTAAGTG-3⬘
and 3⬘-TATAAGGACATTCAC-5⬘ for Stat1 decoy; 5⬘-ATATTGGAGTAAGTG-3⬘ and 3⬘-TATAACCTCATTCAC-5⬘ for
the mismatched Stat1 decoy; 5⬘-GATCCTTCTGGGAATTCCTAGATC-3⬘ and 3⬘-CTAGGAAGACCCTTAAGGATCTAG-5⬘ for the Stat3 decoy; 5⬘-GATCCTTCTGGGCCGTCCTAGATC-3⬘ and 3⬘-CTAGGAAGACCCGGCAGGATCTAG-5⬘ for the mismatched Stat3 decoy; 5⬘-GATCAAGACCTTTTCCCAAGAAATCTAT-3⬘ and 3⬘-CATGTTCTGGAAAAGGGTTCTTTAGATA-5⬘ for Stat6 decoy; and 5⬘-CGAAAATTCGTTAAATCACTAGCTTACC-3⬘ and 3⬘-GCTTTTAAGCAATTTAGTGATCGAATGG-5⬘ for the scrambled decoy ODN for Stat6. Stat1, Stat3, and Stat6 decoy,
mismatched decoy, and scrambled decoy ODN sequences were
prepared by annealing the single-stranded phosphorothioatemodified ODNs as described previously (12, 68). Human
monocytes and A549 cells were then transfected with decoy
ODNs using Superfect Transfection Reagent (Qiagen, Valencia,
CA) according to the manufacturer’s instructions for 24 h.
Monocytes, A549, and U937 cells were further incubated with
IL-13 for another 24 h for MAO-A mRNA quantification or
48 h for either MAO-A protein or native MAO-A enzyme activity detection.
Native MAO-A activity assay
MAO-A activity was measured by a two-step bioluminescent
assay method as described previously (1, 69) using a MAOGLOTM assay kit from Promega (Madison, WI). The amount
of signal (light intensity) generated was detected using a
microplate luminometer (Multilabel Counter Victor3TM,
PerkinElmer Life Sciences). Human recombinant MAO-A
enzyme (Promega) was used as a positive control. The results
are expressed as relative light units after the background was
subtracted.

Intracellular ROS determination
The generation of intracellular ROS was measured using the
ROS-sensitive fluorescent probe H2DCFDA (5 M). After incubation with the probe for 30 min, cells were removed from the
media, scraped off in PBS, washed, and centrifuged. Cell pellet
was resuspended in prewarmed PBS, and the fluorescence was
read (excitation 495 nm; emission 525 nm) as described previously (1, 38, 70).
Amplex Red monoamine oxidase assay
This assay is based on the detection of H2O2 in an HRPcoupled reaction using Amplex Red as a sensitive and stable
probe (for H2O2) and p-tyramine as a substrate. The fluorometric assay was carried out following the manufacturer’s instructions. Each reaction contained 1 mM p-tyramine, 1 unit/ml
HRP, and 200 M Amplex Red reagent. Reactions were incubated at room temperature for 60 min (protected from light),
and fluorescence was measured with a fluorescence microplate
reader using excitation at 571 nm and emission at 585 nm.
Mannose receptor expression by FACS analysis
FACS analyses were performed to assess the expression of
mannose receptor on the surface of monocytes. Monocytes
were harvested from plates by incubating with cell dissociation
buffer (Invitrogen) for 10 min at 37 °C and then washed in PBS.
The cell pellet was resuspended in PBS, and then 2 ⫻ 106 cells
were preincubated with 4% normal goat serum for 30 min at
4 °C. The cells were spun down and then resuspended in 4%
normal goat serum in PBS and incubated with FITC-conjugated mouse anti-human CD206 (macrophage mannose receptor mAb, BD Biosciences) for 30 min at 4 °C according to a
protocol supplied by the manufacturer. Finally, the cells were
washed, resuspended in PBS, and then analyzed using a FACScanTM (BD Biosciences). An appropriate nonspecific isotype
antibody was used as a negative control.
Chemotaxis assay for primary monocytes
Monocyte migration was evaluated using a microchamber
technique (45, 71). DMEM with 15% BSA was added to the
lower compartment of the disposable 96-well chemotaxis
chamber in a total volume of 29 l. The cell suspension (50 l of
2 ⫻ 106 cells/ml and 1 ⫻ 105 cells/well) was added to the upper
compartment of the chamber. The two compartments were
separated by a 5-m pore size, polycarbonate, polyvinylpyrrolidone-free filter. The chamber was incubated at 37 °C with 10%
CO2 for 90 min. At the end of the incubation, the filter facing
the upper compartment was scraped with a sponge and rinsed
gently with PBS to remove all nonmigrated cells. The side of the
filter with the migrated cells was fixed and stained with the
Hema3 stain set. Migrated monocytes were counted in five
high-power fields (⫻400) using a light microscope. All samples
were tested in triplicate, and the data are expressed as the
means ⫾ S.D.
In vitro transwell migration assay
Chemical inhibitors or antisense ODN-treated A549 cells
were used for the transwell migration assay after IL-13 stimuJ. Biol. Chem. (2018) 293(36) 14040 –14064
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lation for a stipulated time period. For this assay, cells (1.5 ⫻
105) were placed in the upper chamber of the cell culture inserts
(catalog no. 353182, BD Biosciences) with 400 l of serum-free
medium and were allowed to migrate for 5 h in response to
complete medium (DMEM with 15% FBS, 600 l) placed in the
bottom chamber of the 12-well transwell plates. Cells that
migrated to the lower surface of the membrane were fixed and
stained with Giemsa, and at least five independent microscopic
fields were counted under microscope.

7.

8.

9.

In vitro cytotoxicity assay
A549 cells (5 ⫻ 105/group) were treated with DMSO and
different doses of pharmacological inhibitors for 96 h. Media
were then removed, and cells were washed with 1⫻ PBS twice.
100 l of cell suspension from each group were seeded in a
96-well microtiter plate and incubated for 4 h. MTT reagent
was then added in each well (final concentration of 0.5 mg/ml)
and incubated for 3 h (in absence of light) at 37 °C in the presence of 5% CO2, and the cell viability was investigated by using
the EZcountTM MTT cell assay kit (HiMedia, Mumbai, India).
The resultant formazan crystals were dissolved in 100 l of
solubilizing solution (supplied in the kit), and the absorbance of
this product was measured at 570 nm using an ELISA plate
reader (MULTISKAN EX Microplate Reader, ThermoFisher
Scientific, Waltham, MA) with the reference wavelength higher
than 650 nm.
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11.

12.

13.

14.

Data analysis
The number of experiments analyzed is indicated in each
figure. Band intensities were quantified by densitometric analyses using a laser densitometer (Microtek ScanMaker 8700,
Cerritos, CA) and the ImageJ software program. Differences
among experimental groups (for dose responses) were analyzed
using one-way ANOVA. The significance of observations was
calculated using unpaired Student’s t test analysis, and p ⬍ 0.05
was considered statistically significant.
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